Mark N Lampert - Insider Trading Tracker

Calithera Biosciences, Inc.

US ˙ OTCPK ˙ US13089P5070

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Mark N Lampert. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Se højest rangerende insidere

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Mark N Lampert har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed	Titel	Senest indberettede beholdninger
US:EPIX / ESSA Pharma Inc.	10% Owner	560.797
US:KYMR / Kymera Therapeutics, Inc.	Director	353.412
	10% Owner	62.383
US:XOMA / XOMA Royalty Corporation	10% Owner	1.267.545
US:ALLK / Allakos Inc.	10% Owner	0
US:OLMA / Olema Pharmaceuticals, Inc.	Director	347.970
		38.961
US:FDMT / 4D Molecular Therapeutics, Inc.		87.911
US: / Third Harmonic Bio, Inc.		176.692
US:MLTX / MoonLake Immunotherapeutics	Director, 10% Owner	1.287.768
US:ELDN / Eledon Pharmaceuticals, Inc.	10% Owner	220.460
	Director	0
US:PNT / POINT Biopharma Global Inc.		0
US:RPTX / Repare Therapeutics Inc.	10% Owner	548.938
	10% Owner	1.204.412
US:CTIC / CTI BioPharma Corp	Director, 10% Owner	0
US:GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock)	10% Owner	0
US:CGEM / Cullinan Therapeutics, Inc.	10% Owner	64.161
US:VSTM / Verastem, Inc.	10% Owner	10.753.294
US:MRUS / Merus N.V.	10% Owner	232.747
	10% Owner	3.372.098
US:INFI / Infinity Pharmaceuticals Inc.	10% Owner	534.847
US:IDYA / IDEAYA Biosciences, Inc.		233.150
US:CTMX / CytomX Therapeutics, Inc.	10% Owner	2.945.743
US:CYTK / Cytokinetics, Incorporated		463.244
	10% Owner	3.547
US:CALA / Calithera Biosciences, Inc.	10% Owner	480.432
US:CNCE / Concert Pharmaceuticals Inc	10% Owner	169.589
US:IMDZ / Immune Design Corp.	10% Owner	370.391
US:SNDX / Syndax Pharmaceuticals, Inc.	10% Owner	188.746
US:ARQL / ArQule, Inc.	10% Owner	771.305
US:XENE / Xenon Pharmaceuticals Inc.	10% Owner	238.000
US:RGLS / Regulus Therapeutics Inc.	10% Owner	17.248.837
US:CAPS / Capstone Holding Corp.		890.487
US:NVLS / Nivalis Therapeutics, Inc.	10% Owner	201.811
US:ONTY / Oncothyreon, Inc.	Director, 10% Owner	6.197
US:CCXI / ChemoCentryx Inc		0
US:04269XAA3 / Array BioPharma Inc. Bonds 3.0% 6/1/2020		7.058.997
US:LGND / Ligand Pharmaceuticals Incorporated		130.175
US:RGDO /		2.632
US:PTN / Palatin Technologies, Inc.	10% Owner	2.494.521
US:RIGL / Rigel Pharmaceuticals, Inc.	10% Owner	646.559
US:TRGT / Targacept	10% Owner	1.713.907

Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Mark N Lampert. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb CALA / Calithera Biosciences, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2019-11-20	CALA	BVF PARTNERS L P/IL	98.518	3,9116	4.926	78,2320	385.363	147	157	387.862	100,65
2019-11-20	CALA	BVF PARTNERS L P/IL	79.285	3,9116	3.964	78,2320	310.131
2019-11-20	CALA	BVF PARTNERS L P/IL	14.151	3,9116	708	78,2320	55.353
2019-11-14	CALA	BVF PARTNERS L P/IL	71.495	3,3700	3.575	67,4000	240.938
2019-11-14	CALA	BVF PARTNERS L P/IL	45.888	3,3700	2.294	67,4000	154.643
2019-11-14	CALA	BVF PARTNERS L P/IL	11.105	3,3700	555	67,4000	37.424
2019-10-30	CALA	BVF PARTNERS L P/IL	408.592	2,7000	20.430	54,0000	1.103.198
2019-10-30	CALA	BVF PARTNERS L P/IL	331.048	2,7000	16.552	54,0000	893.830
2019-10-30	CALA	BVF PARTNERS L P/IL	57.868	2,7000	2.893	54,0000	156.244
2019-10-29	CALA	BVF PARTNERS L P/IL	872.373	2,6000	43.619	52,0000	2.268.170
2019-10-29	CALA	BVF PARTNERS L P/IL	610.052	2,6000	30.503	52,0000	1.586.135
2019-10-29	CALA	BVF PARTNERS L P/IL	116.552	2,6000	5.828	52,0000	303.035

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg CALA / Calithera Biosciences, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2020-05-21 CALA BVF PARTNERS L P/IL 1.027.016 6,0000 51.351 120,0000 6.162.096 354 39.2 -4.149.176 -67,33

2020-05-21 CALA BVF PARTNERS L P/IL 1.064.332 6,0000 53.217 120,0000 6.385.992

2020-05-21 CALA BVF PARTNERS L P/IL 192.250 6,0000 9.612 120,0000 1.153.500

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb CAPS / Capstone Holding Corp. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg CAPS / Capstone Holding Corp. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2017-07-14 CAPS BVF PARTNERS L P/IL 3.993.637 0,0600 3.994 60,0000 239.618 182 0.0450 -239.438 -99,93

2017-07-14 CAPS BVF PARTNERS L P/IL 242.236 0,0600 242 60,0000 14.534

2017-07-14 CAPS BVF PARTNERS L P/IL 105.713 0,0600 106 60,0000 6.343

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb CGEM / Cullinan Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2022-06-01 CGEM BVF PARTNERS L P/IL 405.641 10,9994 405.641 10,9994 4.461.808 48 15.4200 1.793.177 40,19

2022-06-01 CGEM BVF PARTNERS L P/IL 301.009 10,9994 301.009 10,9994 3.310.918

2022-06-01 CGEM BVF PARTNERS L P/IL 44.746 10,9994 44.746 10,9994 492.179

2022-05-13 CGEM BVF PARTNERS L P/IL 53.598 9,1350 53.598 9,1350 489.618

2022-05-13 CGEM BVF PARTNERS L P/IL 38.558 9,1350 38.558 9,1350 352.227

2022-05-13 CGEM BVF PARTNERS L P/IL 17.744 9,1350 17.744 9,1350 162.091

2022-05-12 CGEM BVF PARTNERS L P/IL 542.999 9,0600 542.999 9,0600 4.919.571

2022-05-12 CGEM BVF PARTNERS L P/IL 457.001 9,0600 457.001 9,0600 4.140.429

2022-04-01 CGEM BVF PARTNERS L P/IL 266.598 10,7499 266.598 10,7499 2.865.902

2022-04-01 CGEM BVF PARTNERS L P/IL 9.402 10,7499 9.402 10,7499 101.071

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg CGEM / Cullinan Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb CTMX / CytomX Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg CTMX / CytomX Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb CYTK / Cytokinetics, Incorporated – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2019-12-11 CYTK BVF PARTNERS L P/IL 60.103 9,5150 60.103 9,5150 571.880 217 28.9600 1.168.703 204,36

2019-12-11 CYTK BVF PARTNERS L P/IL 49.804 9,5150 49.804 9,5150 473.885

2019-12-11 CYTK BVF PARTNERS L P/IL 8.506 9,5150 8.506 9,5150 80.935

2019-12-10 CYTK BVF PARTNERS L P/IL 113.529 9,4000 113.529 9,4000 1.067.173

2019-12-10 CYTK BVF PARTNERS L P/IL 95.100 9,4000 95.100 9,4000 893.940

2019-12-10 CYTK BVF PARTNERS L P/IL 15.030 9,4000 15.030 9,4000 141.282

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg CYTK / Cytokinetics, Incorporated – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2020-12-09 CYTK BVF PARTNERS L P/IL 239.274 18,0000 239.274 18,0000 4.306.932 217 18.5400 129.208 3,00

2020-12-09 CYTK BVF PARTNERS L P/IL 166.194 18,0000 166.194 18,0000 2.991.492

2020-12-09 CYTK BVF PARTNERS L P/IL 25.486 18,0000 25.486 18,0000 458.748

2020-02-13 CYTK BVF PARTNERS L P/IL 486.344 15,7868 486.344 15,7868 7.677.815

2020-02-13 CYTK BVF PARTNERS L P/IL 510.793 15,7868 510.793 15,7868 8.063.787

2020-02-13 CYTK BVF PARTNERS L P/IL 74.893 15,7868 74.893 15,7868 1.182.321

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb ELDN / Eledon Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2024-05-09 ELDN BVF PARTNERS L P/IL 1.031.385 1.031.385 176 5.3000

2024-05-09 ELDN BVF PARTNERS L P/IL 821.121 821.121

2024-05-09 ELDN BVF PARTNERS L P/IL 75.431 75.431

2023-05-05 ELDN BVF PARTNERS L P/IL 1.055.445 1.055.445

2023-05-05 ELDN BVF PARTNERS L P/IL 837.146 837.146

2023-05-05 ELDN BVF PARTNERS L P/IL 86.341 86.341

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg ELDN / Eledon Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb EPIX / ESSA Pharma Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg EPIX / ESSA Pharma Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2025-08-05 EPIX BVF PARTNERS L P/IL 79 1,8779 79 1,8779 148 30 0.2316 -130 -87,64

2025-08-05 EPIX BVF PARTNERS L P/IL 66 1,8779 66 1,8779 124

2025-08-05 EPIX BVF PARTNERS L P/IL 11 1,8779 11 1,8779 21

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb FDMT / 4D Molecular Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg FDMT / 4D Molecular Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb IDYA / IDEAYA Biosciences, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2020-06-30 IDYA BVF PARTNERS L P/IL 1.521 13,3164 1.521 13,3164 20.254 279 24.83 17.512 86,46

2020-06-30 IDYA BVF PARTNERS L P/IL 929 13,3164 929 13,3164 12.371

2020-06-30 IDYA BVF PARTNERS L P/IL 81 13,3164 81 13,3164 1.079

2020-06-22 IDYA BVF PARTNERS L P/IL 10.524 13,9347 10.524 13,9347 146.649

2020-06-22 IDYA BVF PARTNERS L P/IL 7.854 13,9347 7.854 13,9347 109.443

2020-06-22 IDYA BVF PARTNERS L P/IL 1.354 13,9347 1.354 13,9347 18.868

2020-06-19 IDYA BVF PARTNERS L P/IL 52.443 14,3895 52.443 14,3895 754.629

2020-06-19 IDYA BVF PARTNERS L P/IL 39.052 14,3895 39.052 14,3895 561.939

2020-06-19 IDYA BVF PARTNERS L P/IL 6.769 14,3895 6.769 14,3895 97.403

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg IDYA / IDEAYA Biosciences, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2021-02-02 IDYA BVF PARTNERS L P/IL 25.234 18,0000 25.234 18,0000 454.212 359 15.2100 -70.403 -15,50

2021-02-02 IDYA BVF PARTNERS L P/IL 16.850 18,0000 16.850 18,0000 303.300

2021-02-02 IDYA BVF PARTNERS L P/IL 4.325 18,0000 4.325 18,0000 77.850

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb INFIQ / Infinity Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2018-12-13 INFI BVF PARTNERS L P/IL 54.461 1,1995 54.461 1,1995 65.326 91 1.9100 38.696 59,24

2018-12-13 INFI BVF PARTNERS L P/IL 120.539 1,1995 120.539 1,1995 144.587

2018-11-28 INFI BVF PARTNERS L P/IL 100.000 1,3000 100.000 1,3000 130.000

2018-11-21 INFI BVF PARTNERS L P/IL 4.119 1,3500 4.119 1,3500 5.561

2018-11-21 INFI BVF PARTNERS L P/IL 581 1,3500 581 1,3500 784

2018-11-19 INFI BVF PARTNERS L P/IL 733.151 1,3698 733.151 1,3698 1.004.270

2018-11-19 INFI BVF PARTNERS L P/IL 556.709 1,3698 556.709 1,3698 762.580

2018-11-19 INFI BVF PARTNERS L P/IL 81.648 1,3698 81.648 1,3698 111.841

2018-11-19 INFI BVF PARTNERS L P/IL 50.044 1,3500 50.044 1,3500 67.559

2018-11-19 INFI BVF PARTNERS L P/IL 38.001 1,3500 38.001 1,3500 51.301

2018-11-19 INFI BVF PARTNERS L P/IL 5.573 1,3500 5.573 1,3500 7.524

2018-11-15 INFI BVF PARTNERS L P/IL 52.400 1,3500 52.400 1,3500 70.740

2018-11-15 INFI BVF PARTNERS L P/IL 39.074 1,3500 39.074 1,3500 52.750

2018-11-14 INFI BVF PARTNERS L P/IL 117.290 1,3400 117.290 1,3400 157.169

2018-11-14 INFI BVF PARTNERS L P/IL 92.960 1,3400 92.960 1,3400 124.566

2018-11-13 INFI BVF PARTNERS L P/IL 41.454 1,3500 41.454 1,3500 55.963

2018-11-13 INFI BVF PARTNERS L P/IL 562.754 1,3500 562.754 1,3500 759.718

2018-06-21 INFI BVF PARTNERS L P/IL 230.555 1,6500 230.555 1,6500 380.416

2018-06-21 INFI BVF PARTNERS L P/IL 158.151 1,6500 158.151 1,6500 260.949

2018-06-21 INFI BVF PARTNERS L P/IL 36.825 1,6500 36.825 1,6500 60.761

2018-06-19 INFI BVF PARTNERS L P/IL 1.916.760 1,6500 1.916.760 1,6500 3.162.654

2018-06-19 INFI BVF PARTNERS L P/IL 1.419.907 1,6500 1.419.907 1,6500 2.342.847

2018-06-19 INFI BVF PARTNERS L P/IL 179.893 1,6500 179.893 1,6500 296.823

2018-04-10 INFI BVF PARTNERS L P/IL 546.865 2,0000 546.865 2,0000 1.093.730

2018-04-10 INFI BVF PARTNERS L P/IL 365.682 2,0000 365.682 2,0000 731.364

2018-04-10 INFI BVF PARTNERS L P/IL 97.453 2,0000 97.453 2,0000 194.906

2018-04-09 INFI BVF PARTNERS L P/IL 228.691 1,9000 228.691 1,9000 434.513

2018-04-09 INFI BVF PARTNERS L P/IL 208.872 1,9000 208.872 1,9000 396.857

2018-04-09 INFI BVF PARTNERS L P/IL 62.437 1,9000 62.437 1,9000 118.630

2017-10-04 INFI BVF PARTNERS L P/IL 355.081 1,2840 355.081 1,2840 455.924

2017-10-04 INFI BVF PARTNERS L P/IL 235.326 1,2840 235.326 1,2840 302.159

2017-10-04 INFI BVF PARTNERS L P/IL 63.042 1,2840 63.042 1,2840 80.946

2017-10-03 INFI BVF PARTNERS L P/IL 523.601 1,2350 523.601 1,2350 646.647

2017-10-03 INFI BVF PARTNERS L P/IL 394.078 1,2350 394.078 1,2350 486.686

2017-10-03 INFI BVF PARTNERS L P/IL 28.918 1,2350 28.918 1,2350 35.714

2017-01-03 INFI BVF PARTNERS L P/IL 1.145 1,3397 1.145 1,3397 1.534

2017-01-03 INFI BVF PARTNERS L P/IL 3.234 1,3397 3.234 1,3397 4.333

2016-12-30 INFI BVF PARTNERS L P/IL 2.348 1,3396 2.348 1,3396 3.145

2016-12-30 INFI BVF PARTNERS L P/IL 1.205 1,3396 1.205 1,3396 1.614

2016-12-28 INFI BVF PARTNERS L P/IL 401.726 1,3356 401.726 1,3356 536.545

2016-12-28 INFI BVF PARTNERS L P/IL 260.046 1,3356 260.046 1,3356 347.317

2016-12-28 INFI BVF PARTNERS L P/IL 77.076 1,3356 77.076 1,3356 102.943

2016-12-20 INFI BVF PARTNERS L P/IL 11.646 1,3549 11.646 1,3549 15.779

2016-12-20 INFI BVF PARTNERS L P/IL 8.111 1,3549 8.111 1,3549 10.990

2016-12-20 INFI BVF PARTNERS L P/IL 2.244 1,3549 2.244 1,3549 3.040

2016-12-19 INFI BVF PARTNERS L P/IL 108.202 1,3584 108.202 1,3584 146.982

2016-12-19 INFI BVF PARTNERS L P/IL 69.041 1,3584 69.041 1,3584 93.785

2016-12-19 INFI BVF PARTNERS L P/IL 21.021 1,3584 21.021 1,3584 28.555

2016-12-16 INFI BVF PARTNERS L P/IL 236.393 1,2800 236.393 1,2800 302.583

2016-12-16 INFI BVF PARTNERS L P/IL 150.451 1,2800 150.451 1,2800 192.577

2016-12-16 INFI BVF PARTNERS L P/IL 47.812 1,2800 47.812 1,2800 61.199

2016-12-02 INFI BVF PARTNERS L P/IL 30.998 1,1901 30.998 1,1901 36.891

2016-12-02 INFI BVF PARTNERS L P/IL 18.586 1,1901 18.586 1,1901 22.119

2016-12-02 INFI BVF PARTNERS L P/IL 2.916 1,1901 2.916 1,1901 3.470

2016-12-01 INFI BVF PARTNERS L P/IL 81.276 1,1845 81.276 1,1845 96.271

2016-12-01 INFI BVF PARTNERS L P/IL 52.457 1,1845 52.457 1,1845 62.135

2016-12-01 INFI BVF PARTNERS L P/IL 15.161 1,1845 15.161 1,1845 17.958

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg INFIQ / Infinity Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2021-02-11 INFI BVF PARTNERS L P/IL 1.215.491 5,3686 1.215.491 5,3686 6.525.485 350 1.1100 -5.176.289 -79,32

2021-02-11 INFI BVF PARTNERS L P/IL 892.467 5,3686 892.467 5,3686 4.791.298

2021-02-11 INFI BVF PARTNERS L P/IL 152.127 5,3686 152.127 5,3686 816.709

2021-01-22 INFI BVF PARTNERS L P/IL 2.821.663 4,1388 2.821.663 4,1388 11.678.299

2021-01-22 INFI BVF PARTNERS L P/IL 2.458.838 4,1388 2.458.838 4,1388 10.176.639

2021-01-22 INFI BVF PARTNERS L P/IL 568.019 4,1388 568.019 4,1388 2.350.917

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb KYMR / Kymera Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2025-06-30 KYMR BVF PARTNERS L P/IL 142.604 44,0000 142.604 44,0000 6.274.576 23 46.4300 346.528 5,52

2025-06-30 KYMR BVF PARTNERS L P/IL 115.783 44,0000 115.783 44,0000 5.094.452

2025-06-30 KYMR BVF PARTNERS L P/IL 58.780 44,0000 58.780 44,0000 2.586.320

2023-11-03 KYMR BVF PARTNERS L P/IL 103.885 14,0689 103.885 14,0689 1.461.548

2023-11-03 KYMR BVF PARTNERS L P/IL 83.708 14,0689 83.708 14,0689 1.177.679

2023-11-03 KYMR BVF PARTNERS L P/IL 10.106 14,0689 10.106 14,0689 142.180

2023-11-02 KYMR BVF PARTNERS L P/IL 57.618 11,6444 57.618 11,6444 670.927

2023-11-02 KYMR BVF PARTNERS L P/IL 132.016 11,6444 132.016 11,6444 1.537.247

2023-11-02 KYMR BVF PARTNERS L P/IL 26.772 11,6444 26.772 11,6444 311.744

2023-01-12 KYMR BVF PARTNERS L P/IL 2.985 31,2426 2.985 31,2426 93.259

2023-01-12 KYMR BVF PARTNERS L P/IL 15.912 31,2426 15.912 31,2426 497.132

2023-01-11 KYMR BVF PARTNERS L P/IL 10.961 29,8869 10.961 29,8869 327.590

2023-01-11 KYMR BVF PARTNERS L P/IL 11.149 29,8869 11.149 29,8869 333.209

2022-08-22 KYMR BVF PARTNERS L P/IL 285.046 26,0000 285.046 26,0000 7.411.196

2022-08-22 KYMR BVF PARTNERS L P/IL 233.362 26,0000 233.362 26,0000 6.067.412

2022-08-22 KYMR BVF PARTNERS L P/IL 27.117 26,0000 27.117 26,0000 705.042

2022-05-27 KYMR BVF PARTNERS L P/IL 35.793 14,7828 35.793 14,7828 529.121

2022-05-27 KYMR BVF PARTNERS L P/IL 26.353 14,7828 26.353 14,7828 389.571

2022-05-27 KYMR BVF PARTNERS L P/IL 3.223 14,7828 3.223 14,7828 47.645

2022-05-26 KYMR BVF PARTNERS L P/IL 123.043 14,2106 123.043 14,2106 1.748.515

2022-05-26 KYMR BVF PARTNERS L P/IL 90.372 14,2106 90.372 14,2106 1.284.240

2022-05-26 KYMR BVF PARTNERS L P/IL 10.642 14,2106 10.642 14,2106 151.229

2022-05-20 KYMR BVF PARTNERS L P/IL 5.883 13,9994 5.883 13,9994 82.358

2022-05-20 KYMR BVF PARTNERS L P/IL 4.180 13,9994 4.180 13,9994 58.517

2022-05-20 KYMR BVF PARTNERS L P/IL 37 13,9994 37 13,9994 518

2022-05-06 KYMR BVF PARTNERS L P/IL 55.210 19,2550 55.210 19,2550 1.063.069

2022-05-06 KYMR BVF PARTNERS L P/IL 40.659 19,2550 40.659 19,2550 782.889

2022-05-06 KYMR BVF PARTNERS L P/IL 4.131 19,2550 4.131 19,2550 79.542

2022-05-05 KYMR BVF PARTNERS L P/IL 75.495 19,5991 75.495 19,5991 1.479.634

2022-05-05 KYMR BVF PARTNERS L P/IL 70.439 19,5991 70.439 19,5991 1.380.541

2022-05-05 KYMR BVF PARTNERS L P/IL 4.066 19,5991 4.066 19,5991 79.690

2022-01-31 KYMR BVF PARTNERS L P/IL 20.085 40,7000 20.085 40,7000 817.460

2022-01-31 KYMR BVF PARTNERS L P/IL 14.323 40,7000 14.323 40,7000 582.946

2022-01-27 KYMR BVF PARTNERS L P/IL 58.042 38,3319 58.042 38,3319 2.224.860

2022-01-27 KYMR BVF PARTNERS L P/IL 37.859 38,3319 37.859 38,3319 1.451.207

2022-01-24 KYMR BVF PARTNERS L P/IL 158.041 37,7635 158.041 37,7635 5.968.181

2022-01-24 KYMR BVF PARTNERS L P/IL 114.726 37,7635 114.726 37,7635 4.332.455

2021-07-01 KYMR BVF PARTNERS L P/IL 304.997 47,0000 304.997 47,0000 14.334.859

2021-07-01 KYMR BVF PARTNERS L P/IL 211.711 47,0000 211.711 47,0000 9.950.417

2021-07-01 KYMR BVF PARTNERS L P/IL 27.458 47,0000 27.458 47,0000 1.290.526

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg KYMR / Kymera Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb MLTX / MoonLake Immunotherapeutics – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg MLTX / MoonLake Immunotherapeutics – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2024-10-04 MLTX BVF PARTNERS L P/IL 1.030.589 50,0016 1.030.589 50,0016 51.531.099 186 32.8350 -17.691.708 -34,33

2024-10-04 MLTX BVF PARTNERS L P/IL 836.862 50,0016 836.862 50,0016 41.844.439

2024-10-04 MLTX BVF PARTNERS L P/IL 132.549 50,0016 132.549 50,0016 6.627.662

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb MRUS / Merus N.V. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2021-03-30 MRUS BVF PARTNERS L P/IL 165.000 19,7500 165.000 19,7500 3.258.750 275 32.29 2.069.100 63,49

2021-03-30 MRUS BVF PARTNERS L P/IL 108.106 19,7500 108.106 19,7500 2.135.094

2021-03-30 MRUS BVF PARTNERS L P/IL 26.894 19,7500 26.894 19,7500 531.156

2021-03-22 MRUS BVF PARTNERS L P/IL 71.756 22,7500 71.756 22,7500 1.632.449

2021-03-22 MRUS BVF PARTNERS L P/IL 7.744 22,7500 7.744 22,7500 176.176

2021-03-16 MRUS BVF PARTNERS L P/IL 53.061 22,9996 53.061 22,9996 1.220.382

2021-03-16 MRUS BVF PARTNERS L P/IL 195.768 22,9996 195.768 22,9996 4.502.586

2021-03-16 MRUS BVF PARTNERS L P/IL 1.171 22,9996 1.171 22,9996 26.933

2021-01-21 MRUS BVF PARTNERS L P/IL 457.814 24,7500 457.814 24,7500 11.330.896

2021-01-21 MRUS BVF PARTNERS L P/IL 343.444 24,7500 343.444 24,7500 8.500.239

2021-01-21 MRUS BVF PARTNERS L P/IL 43.422 24,7500 43.422 24,7500 1.074.694

2020-12-18 MRUS BVF PARTNERS L P/IL 114.968 16,0500 114.968 16,0500 1.845.236

2020-12-18 MRUS BVF PARTNERS L P/IL 45.032 16,0500 45.032 16,0500 722.764

2020-09-15 MRUS BVF PARTNERS L P/IL 77.751 11,7500 77.751 11,7500 913.574

2020-09-15 MRUS BVF PARTNERS L P/IL 58.745 11,7500 58.745 11,7500 690.254

2020-09-15 MRUS BVF PARTNERS L P/IL 10.258 11,7500 10.258 11,7500 120.532

2020-09-10 MRUS BVF PARTNERS L P/IL 100.461 11,0982 100.461 11,0982 1.114.936

2020-09-10 MRUS BVF PARTNERS L P/IL 76.374 11,0982 76.374 11,0982 847.614

2020-09-10 MRUS BVF PARTNERS L P/IL 12.816 11,0982 12.816 11,0982 142.235

2020-09-03 MRUS BVF PARTNERS L P/IL 104.827 11,1700 104.827 11,1700 1.170.918

2020-09-03 MRUS BVF PARTNERS L P/IL 82.740 11,1700 82.740 11,1700 924.206

2020-09-03 MRUS BVF PARTNERS L P/IL 14.339 11,1700 14.339 11,1700 160.167

2020-06-08 MRUS BVF PARTNERS L P/IL 46.966 15,2000 46.966 15,2000 713.883

2020-06-08 MRUS BVF PARTNERS L P/IL 33.321 15,2000 33.321 15,2000 506.479

2020-06-08 MRUS BVF PARTNERS L P/IL 6.967 15,2000 6.967 15,2000 105.898

2020-06-01 MRUS BVF PARTNERS L P/IL 806.443 14,0000 806.443 14,0000 11.290.202

2020-06-01 MRUS BVF PARTNERS L P/IL 561.966 14,0000 561.966 14,0000 7.867.524

2020-06-01 MRUS BVF PARTNERS L P/IL 94.101 14,0000 94.101 14,0000 1.317.414

2020-01-16 MRUS BVF PARTNERS L P/IL 146.442 16,1500 146.442 16,1500 2.365.038

2020-01-16 MRUS BVF PARTNERS L P/IL 112.561 16,1500 112.561 16,1500 1.817.860

2020-01-16 MRUS BVF PARTNERS L P/IL 19.727 16,1500 19.727 16,1500 318.591

2020-01-13 MRUS BVF PARTNERS L P/IL 53.448 14,9784 53.448 14,9784 800.566

2020-01-13 MRUS BVF PARTNERS L P/IL 25.108 14,9784 25.108 14,9784 376.078

2020-01-13 MRUS BVF PARTNERS L P/IL 5.406 14,9784 5.406 14,9784 80.973

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg MRUS / Merus N.V. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2021-10-08 MRUS BVF PARTNERS L P/IL 80.011 27,7865 80.011 27,7865 2.223.226 230 13.9800 -1.104.671 -49,69

2021-10-08 MRUS BVF PARTNERS L P/IL 58.327 27,7865 58.327 27,7865 1.620.703

2021-10-08 MRUS BVF PARTNERS L P/IL 8.929 27,7865 8.929 27,7865 248.106

2021-10-07 MRUS BVF PARTNERS L P/IL 530.999 27,5311 530.999 27,5311 14.618.987

2021-10-07 MRUS BVF PARTNERS L P/IL 384.914 27,5311 384.914 27,5311 10.597.106

2021-10-07 MRUS BVF PARTNERS L P/IL 69.534 27,5311 69.534 27,5311 1.914.348

2021-07-02 MRUS BVF PARTNERS L P/IL 1.106.478 20,7500 1.106.478 20,7500 22.959.418

2021-07-02 MRUS BVF PARTNERS L P/IL 928.739 20,7500 928.739 20,7500 19.271.334

2021-07-02 MRUS BVF PARTNERS L P/IL 150.805 20,7500 150.805 20,7500 3.129.204

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb OLMA / Olema Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2023-09-12 OLMA BVF PARTNERS L P/IL 775.278 9,8400 775.278 9,8400 7.628.736 57 17.1400 5.659.530 74,19

2023-09-12 OLMA BVF PARTNERS L P/IL 677.853 9,8400 677.853 9,8400 6.670.074

2023-09-12 OLMA BVF PARTNERS L P/IL 52.801 9,8400 52.801 9,8400 519.562

2022-06-10 OLMA BVF PARTNERS L P/IL 158.583 4,0345 158.583 4,0345 639.803

2022-06-10 OLMA BVF PARTNERS L P/IL 41.417 4,0345 41.417 4,0345 167.097

2021-11-30 OLMA BVF PARTNERS L P/IL 362.430 9,3903 362.430 9,3903 3.403.326

2021-11-30 OLMA BVF PARTNERS L P/IL 341.977 9,3903 341.977 9,3903 3.211.267

2021-11-30 OLMA BVF PARTNERS L P/IL 35.268 9,3903 35.268 9,3903 331.177

2020-11-19 OLMA BVF PARTNERS L P/IL 613.918 19,0000 613.918 19,0000 11.664.442

2020-11-19 OLMA BVF PARTNERS L P/IL 446.425 19,0000 446.425 19,0000 8.482.075

2020-11-19 OLMA BVF PARTNERS L P/IL 74.991 19,0000 74.991 19,0000 1.424.829

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg OLMA / Olema Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb RIGL / Rigel Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2013-06-07 RIGL BVF PARTNERS L P/IL 24.598 3,4677 2.460 34,6770 85.298 276 47.5 31.504 36,93

2013-06-07 RIGL BVF PARTNERS L P/IL 8.102 3,4677 810 34,6770 28.095

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg RIGL / Rigel Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2013-11-19 RIGL BVF PARTNERS L P/IL 331.566 2,6418 33.157 26,4180 875.931 286 2.6 -789.725 -90,16

2013-11-19 RIGL BVF PARTNERS L P/IL 153.056 2,6418 15.306 26,4180 404.343

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb RPTX / Repare Therapeutics Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2023-11-16 RPTX BVF PARTNERS L P/IL 153.693 5,3837 153.693 5,3837 827.437 88 8.4100 465.121 56,21

2023-11-16 RPTX BVF PARTNERS L P/IL 125.909 5,3837 125.909 5,3837 677.856

2023-11-16 RPTX BVF PARTNERS L P/IL 16.143 5,3837 16.143 5,3837 86.909

2023-11-15 RPTX BVF PARTNERS L P/IL 493.337 4,9999 493.337 4,9999 2.466.636

2023-11-15 RPTX BVF PARTNERS L P/IL 390.507 4,9999 390.507 4,9999 1.952.496

2023-11-15 RPTX BVF PARTNERS L P/IL 47.712 4,9999 47.712 4,9999 238.555

2023-11-02 RPTX BVF PARTNERS L P/IL 218.979 3,6000 218.979 3,6000 788.324

2023-11-02 RPTX BVF PARTNERS L P/IL 492.251 3,6000 492.251 3,6000 1.772.104

2023-11-02 RPTX BVF PARTNERS L P/IL 72.479 3,6000 72.479 3,6000 260.924

2022-06-13 RPTX BVF PARTNERS L P/IL 74.666 12,7300 74.666 12,7300 950.498

2022-06-13 RPTX BVF PARTNERS L P/IL 68.327 12,7300 68.327 12,7300 869.803

2022-06-13 RPTX BVF PARTNERS L P/IL 6.168 12,7300 6.168 12,7300 78.519

2022-06-06 RPTX BVF PARTNERS L P/IL 3.809 13,2118 3.809 13,2118 50.324

2022-06-06 RPTX BVF PARTNERS L P/IL 3.040 13,2118 3.040 13,2118 40.164

2022-06-06 RPTX BVF PARTNERS L P/IL 20 13,2118 20 13,2118 264

2022-06-03 RPTX BVF PARTNERS L P/IL 353.344 12,2860 353.344 12,2860 4.341.184

2022-06-03 RPTX BVF PARTNERS L P/IL 258.797 12,2860 258.797 12,2860 3.179.580

2022-06-03 RPTX BVF PARTNERS L P/IL 31.903 12,2860 31.903 12,2860 391.960

2022-06-02 RPTX BVF PARTNERS L P/IL 660.654 11,6824 660.654 11,6824 7.718.024

2022-06-02 RPTX BVF PARTNERS L P/IL 464.235 11,6824 464.235 11,6824 5.423.379

2022-06-02 RPTX BVF PARTNERS L P/IL 61.156 11,6824 61.156 11,6824 714.449

2022-05-18 RPTX BVF PARTNERS L P/IL 224.388 8,5000 224.388 8,5000 1.907.298

2022-05-18 RPTX BVF PARTNERS L P/IL 189.882 8,5000 189.882 8,5000 1.613.997

2022-05-18 RPTX BVF PARTNERS L P/IL 5.730 8,5000 5.730 8,5000 48.705

2022-01-19 RPTX BVF PARTNERS L P/IL 577.798 14,1000 577.798 14,1000 8.146.952

2022-01-19 RPTX BVF PARTNERS L P/IL 412.264 14,1000 412.264 14,1000 5.812.922

2022-01-19 RPTX BVF PARTNERS L P/IL 7.899 14,1000 7.899 14,1000 111.376

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg RPTX / Repare Therapeutics Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb VSTM / Verastem, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg VSTM / Verastem, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb XENE / Xenon Pharmaceuticals Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2017-08-15 XENE BVF PARTNERS L P/IL 11.429 2,4122 11.429 2,4122 27.569 359 12.1 110.722 401,62

2017-08-15 XENE BVF PARTNERS L P/IL 7.429 2,4122 7.429 2,4122 17.920

2017-08-14 XENE BVF PARTNERS L P/IL 28.007 2,7036 28.007 2,7036 75.720

2017-08-14 XENE BVF PARTNERS L P/IL 13.337 2,7036 13.337 2,7036 36.058

2017-06-27 XENE BVF PARTNERS L P/IL 46.795 4,0000 46.795 4,0000 187.180

2017-06-27 XENE BVF PARTNERS L P/IL 30.170 4,0000 30.170 4,0000 120.680

2017-06-27 XENE BVF PARTNERS L P/IL 8.496 4,0000 8.496 4,0000 33.984

2017-06-27 XENE BVF PARTNERS L P/IL 46.795 3,0361 46.795 3,0361 142.074

2017-06-27 XENE BVF PARTNERS L P/IL 30.170 3,0361 30.170 3,0361 91.599

2017-06-27 XENE BVF PARTNERS L P/IL 8.496 3,0361 8.496 3,0361 25.795

2017-06-19 XENE BVF PARTNERS L P/IL 1.967 3,8500 1.967 3,8500 7.573

2017-06-19 XENE BVF PARTNERS L P/IL 1.271 3,8500 1.271 3,8500 4.893

2017-06-19 XENE BVF PARTNERS L P/IL 357 3,8500 357 3,8500 1.374

2017-06-16 XENE BVF PARTNERS L P/IL 6.097 3,8500 6.097 3,8500 23.473

2017-06-16 XENE BVF PARTNERS L P/IL 3.873 3,8500 3.873 3,8500 14.911

2017-06-16 XENE BVF PARTNERS L P/IL 1.064 3,8500 1.064 3,8500 4.096

2017-06-15 XENE BVF PARTNERS L P/IL 6.774 3,8370 6.774 3,8370 25.992

2017-06-15 XENE BVF PARTNERS L P/IL 3.845 3,8370 3.845 3,8370 14.753

2017-06-15 XENE BVF PARTNERS L P/IL 1.160 3,8370 1.160 3,8370 4.451

2017-06-07 XENE BVF PARTNERS L P/IL 113.446 3,8512 113.446 3,8512 436.903

2017-06-07 XENE BVF PARTNERS L P/IL 73.749 3,8512 73.749 3,8512 284.022

2017-06-07 XENE BVF PARTNERS L P/IL 20.594 3,8512 20.594 3,8512 79.312

2017-06-06 XENE BVF PARTNERS L P/IL 96.736 3,7500 96.736 3,7500 362.760

2017-06-06 XENE BVF PARTNERS L P/IL 53.260 3,7500 53.260 3,7500 199.725

2017-06-06 XENE BVF PARTNERS L P/IL 913 3,7500 913 3,7500 3.424

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg XENE / Xenon Pharmaceuticals Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderkøb XOMAO / XOMA Royalty Corporation - Preferred Stock – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CALA / Calithera Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Maks Pris kl
Maks Maks
Fortjeneste ($) Maks. afkast (%)

2023-01-06 XOMA BVF PARTNERS L P/IL 1.676 21,9817 1.676 21,9817 36.841 14 23.1200 1.908 5,18

2023-01-06 XOMA BVF PARTNERS L P/IL 1.573 21,9817 1.573 21,9817 34.577

2023-01-05 XOMA BVF PARTNERS L P/IL 3.330 18,3852 3.330 18,3852 61.223

2023-01-05 XOMA BVF PARTNERS L P/IL 15.670 18,3852 15.670 18,3852 288.096

2022-09-27 XOMA BVF PARTNERS L P/IL 1.004 16,8902 1.004 16,8902 16.958

2022-09-27 XOMA BVF PARTNERS L P/IL 678 16,8902 678 16,8902 11.452

2022-09-26 XOMA BVF PARTNERS L P/IL 3.339 16,8317 3.339 16,8317 56.201

2022-09-26 XOMA BVF PARTNERS L P/IL 3.021 16,8317 3.021 16,8317 50.849

2022-09-23 XOMA BVF PARTNERS L P/IL 6.715 16,4970 6.715 16,4970 110.777

2022-09-23 XOMA BVF PARTNERS L P/IL 9.885 16,4970 9.885 16,4970 163.073

2022-09-16 XOMA BVF PARTNERS L P/IL 10.897 17,8873 10.897 17,8873 194.918

2022-09-16 XOMA BVF PARTNERS L P/IL 13.396 17,8873 13.396 17,8873 239.618

2022-09-15 XOMA BVF PARTNERS L P/IL 5.575 17,9620 5.575 17,9620 100.138

2022-09-14 XOMA BVF PARTNERS L P/IL 26.441 17,2476 26.441 17,2476 456.044

2020-09-23 XOMA BVF PARTNERS L P/IL 9.888 18,1998 9.888 18,1998 179.960

2020-09-23 XOMA BVF PARTNERS L P/IL 7.201 18,1998 7.201 18,1998 131.057

2020-09-22 XOMA BVF PARTNERS L P/IL 6.960 18,4457 6.960 18,4457 128.382

2020-09-22 XOMA BVF PARTNERS L P/IL 4.991 18,4457 4.991 18,4457 92.062

2020-09-21 XOMA BVF PARTNERS L P/IL 12.259 18,3851 12.259 18,3851 225.383

2020-09-21 XOMA BVF PARTNERS L P/IL 10.069 18,3851 10.069 18,3851 185.120

2020-09-04 XOMA BVF PARTNERS L P/IL 3.907 18,7706 3.907 18,7706 73.337

2020-09-04 XOMA BVF PARTNERS L P/IL 3.830 18,7706 3.830 18,7706 71.891

2020-09-01 XOMA BVF PARTNERS L P/IL 9.900 18,8661 9.900 18,8661 186.774

2020-09-01 XOMA BVF PARTNERS L P/IL 7.672 18,8661 7.672 18,8661 144.741

2020-08-31 XOMA BVF PARTNERS L P/IL 9.143 18,4806 9.143 18,4806 168.968

2020-08-31 XOMA BVF PARTNERS L P/IL 6.862 18,4806 6.862 18,4806 126.814

2020-08-28 XOMA BVF PARTNERS L P/IL 1.122 19,1719 1.122 19,1719 21.511

2020-08-28 XOMA BVF PARTNERS L P/IL 922 19,1719 922 19,1719 17.676

2020-08-25 XOMA BVF PARTNERS L P/IL 3.443 19,7450 3.443 19,7450 67.982

2020-08-25 XOMA BVF PARTNERS L P/IL 2.244 19,7450 2.244 19,7450 44.308

2020-08-24 XOMA BVF PARTNERS L P/IL 6.504 19,3093 6.504 19,3093 125.588

2020-08-24 XOMA BVF PARTNERS L P/IL 5.179 19,3093 5.179 19,3093 100.003

2020-08-21 XOMA BVF PARTNERS L P/IL 9.198 19,3216 9.198 19,3216 177.720

2020-08-21 XOMA BVF PARTNERS L P/IL 1.607 19,3216 1.607 19,3216 31.050

2020-08-20 XOMA BVF PARTNERS L P/IL 1.772 19,1200 1.772 19,1200 33.881

2020-08-19 XOMA BVF PARTNERS L P/IL 3.496 19,7016 3.496 19,7016 68.877

2020-08-18 XOMA BVF PARTNERS L P/IL 895 19,2694 895 19,2694 17.246

2020-08-14 XOMA BVF PARTNERS L P/IL 21.922 18,6940 21.922 18,6940 409.810

2020-08-13 XOMA BVF PARTNERS L P/IL 1.050 17,8032 1.050 17,8032 18.693

2020-08-12 XOMA BVF PARTNERS L P/IL 4.050 17,3415 4.050 17,3415 70.233

2020-03-25 XOMA BVF PARTNERS L P/IL 8.264 17,1986 8.264 17,1986 142.129

2020-03-18 XOMA BVF PARTNERS L P/IL 4.439 14,5246 4.439 14,5246 64.475

2020-03-17 XOMA BVF PARTNERS L P/IL 8.113 15,7337 8.113 15,7337 127.648

2020-03-16 XOMA BVF PARTNERS L P/IL 10.164 15,7336 10.164 15,7336 159.916

2020-03-13 XOMA BVF PARTNERS L P/IL 100.000 18,3409 100.000 18,3409 1.834.090

2019-12-19 XOMA BVF PARTNERS L P/IL 207.234 22,0000 207.234 22,0000 4.559.148

2019-12-19 XOMA BVF PARTNERS L P/IL 165.961 22,0000 165.961 22,0000 3.651.142

2019-05-14 XOMA BVF PARTNERS L P/IL 13.816 14,7412 13.816 14,7412 203.664

2019-05-13 XOMA BVF PARTNERS L P/IL 3.797 14,3604 3.797 14,3604 54.526

2019-05-10 XOMA BVF PARTNERS L P/IL 10.300 14,5667 10.300 14,5667 150.037

2018-12-17 XOMA BVF PARTNERS L P/IL 25.000 14,1917 25.000 14,1917 354.792

2018-12-13 XOMA BVF PARTNERS L P/IL 24.253 14,4116 24.253 14,4116 349.525

2018-12-12 XOMA BVF PARTNERS L P/IL 2.810 14,7500 2.810 14,7500 41.448

2018-12-11 XOMA BVF PARTNERS L P/IL 9.400 14,4968 9.400 14,4968 136.270

2018-12-10 XOMA BVF PARTNERS L P/IL 18.081 14,5441 18.081 14,5441 262.972

2018-12-07 XOMA BVF PARTNERS L P/IL 32.015 14,7674 32.015 14,7674 472.778

2018-12-06 XOMA BVF PARTNERS L P/IL 10.927 14,7980 10.927 14,7980 161.698

2018-12-04 XOMA BVF PARTNERS L P/IL 4.171 14,9880 4.171 14,9880 62.515

2018-12-03 XOMA BVF PARTNERS L P/IL 806 14,9000 806 14,9000 12.009

2018-11-30 XOMA BVF PARTNERS L P/IL 4.823 14,8486 4.823 14,8486 71.615

2018-11-29 XOMA BVF PARTNERS L P/IL 10.016 14,9304 10.016 14,9304 149.543

2018-11-28 XOMA BVF PARTNERS L P/IL 8.288 15,1136 8.288 15,1136 125.262

2018-11-27 XOMA BVF PARTNERS L P/IL 11.396 15,2404 11.396 15,2404 173.680

2018-11-21 XOMA BVF PARTNERS L P/IL 25.000 14,9957 25.000 14,9957 374.892

2018-11-20 XOMA BVF PARTNERS L P/IL 37.482 13,6786 37.482 13,6786 512.701

2018-11-19 XOMA BVF PARTNERS L P/IL 9.771 13,9253 9.771 13,9253 136.064

2018-11-16 XOMA BVF PARTNERS L P/IL 10.849 13,8249 10.849 13,8249 149.986

2018-11-15 XOMA BVF PARTNERS L P/IL 21.141 13,3088 21.141 13,3088 281.361

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insidersalg XOMAO / XOMA Royalty Corporation - Preferred Stock – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CALA / Calithera Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier Rapporteret
Pris Justeret
Aktier Justeret
Pris Omkostningsgrundlag dage til
Min Pris kl
Min Max tab
Undgået ($) Max tab
Undgået (%)

2025-05-16 XOMA BVF PARTNERS L P/IL 127.407 27,1000 127.407 27,1000 3.452.730 28 23.8500 -414.072 -11,99

2025-05-16 XOMA BVF PARTNERS L P/IL 265.316 27,1000 265.316 27,1000 7.190.064

2025-01-24 XOMA BVF PARTNERS L P/IL 339.679 26,1000 339.679 26,1000 8.865.622

2025-01-24 XOMA BVF PARTNERS L P/IL 85.776 26,1000 85.776 26,1000 2.238.754

2025-01-24 XOMA BVF PARTNERS L P/IL 75.287 26,1000 75.287 26,1000 1.964.991

2025-01-24 XOMA BVF PARTNERS L P/IL 149.975 26,1000 149.975 26,1000 3.914.348

2021-03-31 XOMA BVF PARTNERS L P/IL 279.740 38,3600 279.740 38,3600 10.730.826

2021-03-31 XOMA BVF PARTNERS L P/IL 205.807 38,3600 205.807 38,3600 7.894.757

2021-03-31 XOMA BVF PARTNERS L P/IL 84.250 38,3600 84.250 38,3600 3.231.830

2021-03-31 XOMA BVF PARTNERS L P/IL 81.903 38,3600 81.903 38,3600 3.141.799

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Mark N Lampert som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om Del
Pris Tran
Værdi Tilbage
Værdi

2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock S - Sale -11 560.797 0,00 1,88 -21 1.053.121

2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock S - Sale -66 4.726.743 0,00 1,88 -124 8.876.351

2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock S - Sale -79 6.194.145 0,00 1,88 -148 11.631.985

2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock X - Other 203.336 560.808 56,88 0,00 20 56

2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock X - Other 1.235.030 4.726.809 35,37 0,00 124 473

2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock X - Other 1.481.634 6.194.224 31,44 0,00 148 619

2025-07-01 2025-06-30 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 58.780 353.412 19,95 44,00 2.586.320 15.550.128

2025-07-01 2025-06-30 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 115.783 2.219.858 5,50 44,00 5.094.452 97.673.752

2025-07-01 2025-06-30 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 142.604 2.798.795 5,37 44,00 6.274.576 123.146.980

2025-06-17 2025-06-13 4 CBIO GLYCOMIMETICS INC
Common Stock J - Other 56.079 62.383 889,58

2025-06-17 2025-06-13 4 CBIO GLYCOMIMETICS INC
Common Stock J - Other 556.617 593.740 1.499,39

2025-06-17 2025-06-13 4 CBIO GLYCOMIMETICS INC
Common Stock J - Other 657.308 707.116 1.319,68

2025-05-20 2025-05-16 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share S - Sale -265.316 1.267.545 -17,31 27,10 -7.190.064 34.350.470

2025-05-20 2025-05-16 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share S - Sale -127.407 1.322.758 -8,79 27,10 -3.452.730 35.846.742

2025-05-19 2025-05-15 4 ALLK Allakos Inc.
Common Stock, $0.001 par value D - Sale to Issuer -855.211 0 -100,00

2025-05-19 2025-05-15 4 ALLK Allakos Inc.
Common Stock, $0.001 par value D - Sale to Issuer -6.777.935 0 -100,00

2025-05-19 2025-05-15 4 ALLK Allakos Inc.
Common Stock, $0.001 par value D - Sale to Issuer -8.679.726 0 -100,00

2025-01-28 2025-01-24 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share S - Sale -149.975 0 -100,00 26,10 -3.914.348

2025-01-28 2025-01-24 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share S - Sale -75.287 0 -100,00 26,10 -1.964.991

2025-01-28 2025-01-24 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share S - Sale -85.776 1.532.861 -5,30 26,10 -2.238.754 40.007.672

2025-01-28 2025-01-24 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share S - Sale -339.679 1.450.165 -18,98 26,10 -8.865.622 37.849.306

2025-01-14 2025-01-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value D - Sale to Issuer -22.740 347.970 -6,13

2025-01-14 2025-01-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value D - Sale to Issuer -161.810 2.003.966 -7,47

2025-01-14 2025-01-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value D - Sale to Issuer -235.450 2.655.977 -8,14

2024-12-17 2024-12-13 4 PVLA PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value J - Other 29.648 38.961 318,35

2024-12-17 2024-12-13 4 PVLA PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value J - Other 174.958 282.223 163,11

2024-12-17 2024-12-13 4 PVLA PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value J - Other 234.323 371.916 170,30

2024-12-04 2024-12-04 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value D - Sale to Issuer -153.441 370.710 -29,27

2024-12-04 2024-12-04 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value D - Sale to Issuer -1.418.736 2.165.776 -39,58

2024-12-04 2024-12-04 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value D - Sale to Issuer -1.797.527 2.891.427 -38,34

2024-11-13 2024-11-08 4 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value J - Other -240.000 87.911 -73,19

2024-11-13 2024-11-08 4 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value J - Other -2.378.000 662.970 -78,20

2024-11-13 2024-11-08 4 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value J - Other -3.062.000 830.237 -78,67

2024-10-31 2024-10-29 4 THRD Third Harmonic Bio, Inc.
Common Stock S - Sale -64.617 176.692 -26,78 14,30 -924.023 2.526.696

2024-10-31 2024-10-29 4 THRD Third Harmonic Bio, Inc.
Common Stock S - Sale -396.963 1.367.257 -22,50 14,30 -5.676.571 19.551.775

2024-10-31 2024-10-29 4 THRD Third Harmonic Bio, Inc.
Common Stock S - Sale -538.420 1.794.218 -23,08 14,30 -7.699.406 25.657.317

2024-10-08 2024-10-04 4 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value S - Sale -132.549 1.287.768 -9,33 50,00 -6.627.662 64.390.460

2024-10-08 2024-10-04 4 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value S - Sale -836.862 8.168.838 -9,29 50,00 -41.844.439 408.454.970

2024-10-08 2024-10-04 4 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value S - Sale -1.030.589 10.235.089 -9,15 50,00 -51.531.099 511.770.826

2024-08-01 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value 3.892.237

2024-08-01 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value 3.040.970

2024-08-01 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value 327.911

2024-05-13 2024-05-09 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value P - Purchase 75.431 220.460 52,01

2024-05-13 2024-05-09 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value P - Purchase 821.121 2.633.679 45,30

2024-05-13 2024-05-09 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value P - Purchase 1.031.385 3.361.803 44,26

2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value U - Other -341.547 0 -100,00

2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Common Stock, $0.001 par value U - Other -185.388 0 -100,00

2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value U - Other -2.076.085 0 -100,00

2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Common Stock, $0.001 par value U - Other -1.367.838 0 -100,00

2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value U - Other -2.870.985 0 -100,00

2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Common Stock, $0.001 par value U - Other -1.734.960 0 -100,00

2024-01-26 3 ALLK Allakos Inc.
Common Stock, $0.001 par value 8.679.726

2024-01-26 3 ALLK Allakos Inc.
Common Stock, $0.001 par value 6.777.935

2024-01-26 3 ALLK Allakos Inc.
Common Stock, $0.001 par value 855.211

2023-12-20 2023-12-18 4 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value S - Sale -896.366 0 -100,00 12,45 -11.159.757

2023-12-20 2023-12-18 4 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value S - Sale -7.290.667 0 -100,00 12,45 -90.768.804

2023-12-20 2023-12-18 4 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value S - Sale -8.974.245 0 -100,00 12,45 -111.729.350

2023-11-17 2023-11-16 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 16.143 548.938 3,03 5,38 86.909 2.955.318

2023-11-17 2023-11-16 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 125.909 4.308.573 3,01 5,38 677.856 23.196.064

2023-11-17 2023-11-16 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 153.693 5.309.432 2,98 5,38 827.437 28.584.389

2023-11-17 2023-11-15 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 47.712 532.795 9,84 5,00 238.555 2.663.922

2023-11-17 2023-11-15 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 390.507 4.182.664 10,30 5,00 1.952.496 20.912.902

2023-11-17 2023-11-15 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 493.337 5.155.739 10,58 5,00 2.466.636 25.778.179

2023-11-13 3 ENGN enGene Holdings Inc.
Class A Common Shares 1.204.412

2023-11-13 3 ENGN enGene Holdings Inc.
Class A Common Shares 912.776

2023-11-13 3 ENGN enGene Holdings Inc.
Class A Common Shares 104.257

2023-11-06 3 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value 8.974.245

2023-11-06 3 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value 7.290.667

2023-11-06 3 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value 896.366

2023-11-06 2023-11-03 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 10.106 294.632 3,55 14,07 142.180 4.145.148

2023-11-06 2023-11-03 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 83.708 2.104.075 4,14 14,07 1.177.679 29.602.021

2023-11-06 2023-11-03 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 103.885 2.656.191 4,07 14,07 1.461.548 37.369.686

2023-11-06 2023-11-02 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 26.772 284.526 10,39 11,64 311.744 3.313.135

2023-11-06 2023-11-02 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 132.016 2.020.367 6,99 11,64 1.537.247 23.525.961

2023-11-06 2023-11-02 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 57.618 2.552.306 2,31 11,64 670.927 29.720.072

2023-11-03 2023-11-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 72.479 485.083 17,57 3,60 260.924 1.746.299

2023-11-03 2023-11-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 492.251 3.792.157 14,92 3,60 1.772.104 13.651.765

2023-11-03 2023-11-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 218.979 4.662.402 4,93 3,60 788.324 16.784.647

2023-09-14 2023-09-14 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value J - Other 99.556 99.556

2023-09-14 2023-09-12 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 52.801 524.151 11,20 9,84 519.562 5.157.646

2023-09-14 2023-09-12 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 677.853 3.584.512 23,32 9,84 6.670.074 35.271.598

2023-09-14 2023-09-12 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 775.278 4.688.954 19,81 9,84 7.628.736 46.139.307

2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 U - Other -43.139 0 -100,00 9,10 -392.565

2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 U - Other -1.526.147 0 -100,00 9,10 -13.887.938

2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 U - Other -702.505 0 -100,00 9,10 -6.392.796

2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 U - Other -2.595.239 0 -100,00 9,10 -23.616.675

2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 U - Other -3.989.130 0 -100,00 9,10 -36.301.083

2023-05-22 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 11.007.420

2023-05-22 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 8.581.171

2023-05-22 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 744.966

2023-05-12 2023-05-10 4 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share J - Other -462.605 0 -100,00

2023-05-12 2023-05-10 4 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share J - Other -2.929.660 0 -100,00

2023-05-12 2023-05-10 4 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share J - Other -4.018.253 0 -100,00

2023-05-09 2023-05-05 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value P - Purchase 86.341 145.029 147,12

2023-05-09 2023-05-05 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value P - Purchase 837.146 1.812.558 85,82

2023-05-09 2023-05-05 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value P - Purchase 1.055.445 2.330.418 82,78

2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 4.018.253

2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 2.801.529

2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 2.929.660

2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 2.130.657

2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 462.605

2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 241.755

2023-01-19 2023-01-19 4 CGEM Cullinan Oncology, Inc.
Common Stock J - Other -300.000 64.161 -82,38

2023-01-19 2023-01-19 4 CGEM Cullinan Oncology, Inc.
Common Stock J - Other -2.600.000 392.808 -86,87

2023-01-19 2023-01-19 4 CGEM Cullinan Oncology, Inc.
Common Stock J - Other -3.500.000 558.854 -86,23

2023-01-13 2023-01-12 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 15.912 1.888.351 0,85 31,24 497.132 58.996.995

2023-01-13 2023-01-12 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 2.985 2.494.688 0,12 31,24 93.259 77.940.539

2023-01-13 2023-01-11 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 11.149 1.872.439 0,60 29,89 333.209 55.961.397

2023-01-13 2023-01-11 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 10.961 2.491.703 0,44 29,89 327.590 74.469.278

2023-01-09 2023-01-06 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 1.573 1.618.637 0,10 21,98 34.577 35.580.393

2023-01-09 2023-01-06 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 1.676 1.789.844 0,09 21,98 36.841 39.343.814

2023-01-09 2023-01-05 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 15.670 1.617.064 0,98 18,39 288.096 29.730.045

2023-01-09 2023-01-05 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 3.330 1.788.168 0,19 18,39 61.223 32.875.826

2022-12-22 2022-12-20 4 THRD Third Harmonic Bio, Inc.
Common Stock P - Purchase 9.597 241.309 4,14 4,11 39.430 991.442

2022-12-22 2022-12-20 4 THRD Third Harmonic Bio, Inc.
Common Stock P - Purchase 87.831 1.764.220 5,24 4,11 360.862 7.248.474

2022-12-22 2022-12-20 4 THRD Third Harmonic Bio, Inc.
Common Stock P - Purchase 116.635 2.332.638 5,26 4,11 479.207 9.583.876

2022-12-22 3 THRD Third Harmonic Bio, Inc.
Common Stock 2.216.003

2022-12-22 3 THRD Third Harmonic Bio, Inc.
Common Stock 1.676.389

2022-12-22 3 THRD Third Harmonic Bio, Inc.
Common Stock 231.712

2022-11-10 2022-11-08 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value P - Purchase 54.857 341.547 19,13 5,83 319.816 1.991.219

2022-11-10 2022-11-08 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value P - Purchase 685.330 2.076.085 49,28 5,83 3.995.474 12.103.576

2022-11-10 2022-11-08 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value P - Purchase 970.171 2.870.985 51,04 5,83 5.656.097 16.737.843

2022-09-27 2022-09-27 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 678 1.601.394 0,04 16,89 11.452 27.047.865

2022-09-27 2022-09-27 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 1.004 1.784.838 0,06 16,89 16.958 30.146.271

2022-09-27 2022-09-26 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 3.021 1.600.716 0,19 16,83 50.849 26.942.771

2022-09-27 2022-09-26 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 3.339 1.783.834 0,19 16,83 56.201 30.024.959

2022-09-27 2022-09-23 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 9.885 1.597.695 0,62 16,50 163.073 26.357.174

2022-09-27 2022-09-23 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 6.715 1.780.495 0,38 16,50 110.777 29.372.826

2022-09-16 2022-09-16 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 13.396 1.773.780 0,76 17,89 239.618 31.728.135

2022-09-16 2022-09-16 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 10.897 1.587.810 0,69 17,89 194.918 28.401.634

2022-09-16 2022-09-15 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 5.575 1.576.913 0,35 17,96 100.138 28.324.511

2022-09-16 2022-09-14 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 26.441 1.571.338 1,71 17,25 456.044 27.101.809

2022-08-23 2022-08-22 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 27.117 257.754 11,76 26,00 705.042 6.701.604

2022-08-23 2022-08-22 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 233.362 1.861.290 14,33 26,00 6.067.412 48.393.540

2022-08-23 2022-08-22 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 285.046 2.480.742 12,98 26,00 7.411.196 64.499.292

2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 C - Conversion 1.519.999 1.526.147 24.723,47

2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 S - Sale -1.289.434 6.148 -99,53 6,12 -7.891.336 37.626

2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 C - Conversion 682.666 702.505 3.441,03

2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 S - Sale -469.040 19.839 -95,94 6,12 -2.870.525 121.415

2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 C - Conversion 2.426.666 2.595.239 1.439,53

2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 S - Sale -2.890.723 168.573 -94,49 6,12 -17.691.225 1.031.667

2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 C - Conversion 3.754.000 3.989.130 1.596,56

2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 S - Sale -3.850.803 235.130 -94,25 6,12 -23.566.914 1.438.996

2022-07-21 3 EPIX ESSA Pharma Inc.
Common Stock 4.712.590

2022-07-21 3 EPIX ESSA Pharma Inc.
Common Stock 3.491.779

2022-07-21 3 EPIX ESSA Pharma Inc.
Common Stock 357.472

2022-06-27 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock 2.132.411

2022-06-27 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock 1.570.857

2022-06-27 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock 209.716

2022-06-15 2022-06-13 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 6.168 412.604 1,52 12,73 78.519 5.252.449

2022-06-15 2022-06-13 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 68.327 3.299.906 2,11 12,73 869.803 42.007.803

2022-06-15 2022-06-13 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 74.666 4.443.423 1,71 12,73 950.498 56.564.775

2022-06-14 2022-06-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 41.417 2.906.659 1,45 4,03 167.097 11.726.916

2022-06-14 2022-06-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 158.583 3.913.676 4,22 4,03 639.803 15.789.726

2022-06-06 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 20 406.436 0,00 13,21 264 5.369.751

2022-06-06 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 3.040 3.231.579 0,09 13,21 40.164 42.694.975

2022-06-06 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 3.809 4.368.757 0,09 13,21 50.324 57.719.144

2022-06-06 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 31.903 406.416 8,52 12,29 391.960 4.993.227

2022-06-06 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 258.797 3.228.539 8,71 12,29 3.179.580 39.665.830

2022-06-06 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 353.344 4.364.948 8,81 12,29 4.341.184 53.627.751

2022-06-06 2022-06-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 61.156 374.513 19,52 11,68 714.449 4.375.211

2022-06-06 2022-06-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 464.235 2.969.742 18,53 11,68 5.423.379 34.693.714

2022-06-06 2022-06-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 660.654 4.011.604 19,72 11,68 7.718.024 46.865.163

2022-06-03 2022-06-01 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 44.746 364.161 14,01 11,00 492.179 4.005.553

2022-06-03 2022-06-01 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 301.009 2.992.808 11,18 11,00 3.310.918 32.919.092

2022-06-03 2022-06-01 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 405.641 4.058.854 11,10 11,00 4.461.808 44.644.959

2022-05-31 2022-05-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 3.223 230.637 1,42 14,78 47.645 3.409.461

2022-05-31 2022-05-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 26.353 1.627.928 1,65 14,78 389.571 24.065.334

2022-05-31 2022-05-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 35.793 2.195.696 1,66 14,78 529.121 32.458.535

2022-05-31 2022-05-26 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 10.642 227.414 4,91 14,21 151.229 3.231.689

2022-05-31 2022-05-26 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 90.372 1.601.575 5,98 14,21 1.284.240 22.759.342

2022-05-31 2022-05-26 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 123.043 2.159.903 6,04 14,21 1.748.515 30.693.518

2022-05-24 2022-05-20 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 37 216.772 0,02 14,00 518 3.034.678

2022-05-24 2022-05-20 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 4.180 1.511.203 0,28 14,00 58.517 21.155.935

2022-05-24 2022-05-20 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 5.883 2.036.860 0,29 14,00 82.358 28.514.818

2022-05-20 2022-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 5.730 313.357 1,86 8,50 48.705 2.663.534

2022-05-20 2022-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 189.882 2.505.507 8,20 8,50 1.613.997 21.296.810

2022-05-20 2022-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 224.388 3.350.950 7,18 8,50 1.907.298 28.483.075

2022-05-20 2022-05-18 4 XOMA XOMA Corp
Non-Qualified Stock Option (right to buy) A - Award 8.996 8.996

2022-05-16 2022-05-13 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 17.744 319.415 5,88 9,14 162.091 2.917.856

2022-05-16 2022-05-13 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 38.558 2.691.799 1,45 9,14 352.227 24.589.584

2022-05-16 2022-05-13 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 53.598 3.653.213 1,49 9,14 489.618 33.372.101

2022-05-16 2022-05-12 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 457.001 2.653.241 20,81 9,06 4.140.429 24.038.363

2022-05-16 2022-05-12 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 542.999 3.599.615 17,76 9,06 4.919.571 32.612.512

2022-05-09 2022-05-06 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 4.131 216.735 1,94 19,26 79.542 4.173.232

2022-05-09 2022-05-06 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 40.659 1.507.023 2,77 19,26 782.889 29.017.728

2022-05-09 2022-05-06 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 55.210 2.030.977 2,79 19,26 1.063.069 39.106.462

2022-05-09 2022-05-05 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 4.066 212.604 1,95 19,60 79.690 4.166.847

2022-05-09 2022-05-05 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 70.439 1.466.364 5,05 19,60 1.380.541 28.739.415

2022-05-09 2022-05-05 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 75.495 1.975.767 3,97 19,60 1.479.634 38.723.255

2022-04-15 3 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value 11.265.678

2022-04-15 3 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value 9.005.699

2022-04-15 3 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value 1.420.317

2022-04-05 2022-04-01 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 9.402 2.196.240 0,43 10,75 101.071 23.609.360

2022-04-05 2022-04-01 4 CGEM Cullinan Oncology, Inc.
Common Stock P - Purchase 266.598 3.056.616 9,56 10,75 2.865.902 32.858.316

2022-03-11 2022-03-09 4 CTIC CTI BIOPHARMA CORP
Stock Option (Right to Buy) A - Award 80.000 80.000

2022-02-07 3 VSTM Verastem, Inc.
Common Stock 10.753.294

2022-02-07 3 VSTM Verastem, Inc.
Common Stock 7.883.287

2022-02-07 3 VSTM Verastem, Inc.
Common Stock 994.353

2022-01-31 2022-01-31 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 14.323 1.395.925 1,04 40,70 582.946 56.814.148

2022-01-31 2022-01-31 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 20.085 1.900.272 1,07 40,70 817.460 77.341.070

2022-01-31 2022-01-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 37.859 1.381.602 2,82 38,33 1.451.207 52.959.430

2022-01-31 2022-01-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 58.042 1.880.187 3,19 38,33 2.224.860 72.071.140

2022-01-31 3 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 1.274.973

2022-01-31 3 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 975.412

2022-01-31 3 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 58.688

2022-01-26 2022-01-24 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 114.726 1.343.743 9,33 37,76 4.332.455 50.744.439

2022-01-26 2022-01-24 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 158.041 1.822.145 9,50 37,76 5.968.181 68.810.573

2022-01-21 2022-01-19 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 7.899 307.627 2,64 14,10 111.376 4.337.541

2022-01-21 2022-01-19 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 412.264 2.315.625 21,66 14,10 5.812.922 32.650.312

2022-01-21 2022-01-19 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value P - Purchase 577.798 3.126.562 22,67 14,10 8.146.952 44.084.524

2022-01-10 3 CGEM Cullinan Oncology, Inc.
Common Stock 2.790.018

2022-01-10 3 CGEM Cullinan Oncology, Inc.
Common Stock 2.186.838

2022-01-10 3 CGEM Cullinan Oncology, Inc.
Common Stock 301.671

2022-01-10 2022-01-07 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 14.806 185.388 8,68 12,00 177.672 2.224.656

2022-01-10 2022-01-07 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 226.079 1.367.838 19,80 12,00 2.712.948 16.414.056

2022-01-10 2022-01-07 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 255.500 1.734.960 17,27 12,00 3.066.000 20.819.520

2022-01-10 2022-01-06 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 61.343 1.141.759 5,68 12,00 736.018 13.699.281

2021-12-02 2021-11-30 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 35.268 471.350 8,09 9,39 331.177 4.426.118

2021-12-02 2021-11-30 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 341.977 2.865.242 13,55 9,39 3.211.267 26.905.482

2021-12-02 2021-11-30 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 362.430 3.755.093 10,68 9,39 3.403.326 35.261.450

2021-11-08 3 RPTX Repare Therapeutics Inc.
Common Stock 2.548.764

2021-11-08 3 RPTX Repare Therapeutics Inc.
Common Stock 1.903.361

2021-11-08 3 RPTX Repare Therapeutics Inc.
Common Stock 299.728

2021-10-08 2021-10-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share S - Sale -8.929 232.747 -3,69 27,79 -248.106 6.467.225

2021-10-08 2021-10-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share S - Sale -58.327 1.520.405 -3,69 27,79 -1.620.703 42.246.734

2021-10-08 2021-10-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share S - Sale -80.011 2.085.664 -3,69 27,79 -2.223.226 57.953.303

2021-10-08 2021-10-07 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share S - Sale -69.534 241.676 -22,34 27,53 -1.914.348 6.653.606

2021-10-08 2021-10-07 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share S - Sale -384.914 1.578.732 -19,60 27,53 -10.597.106 43.464.229

2021-10-08 2021-10-07 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share S - Sale -530.999 2.165.675 -19,69 27,53 -14.618.987 59.623.415

2021-09-23 2021-09-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 590 170.582 0,35 13,94 8.226 2.378.357

2021-09-23 2021-09-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 4.102 1.080.416 0,38 13,94 57.193 15.063.808

2021-09-23 2021-09-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 6.341 1.479.460 0,43 13,94 88.410 20.627.519

2021-09-15 2021-09-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 20.512 169.992 13,72 16,49 338.243 2.803.168

2021-09-15 2021-09-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 158.511 1.076.314 17,27 16,49 2.613.846 17.748.418

2021-09-15 2021-09-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 213.246 1.473.119 16,93 16,49 3.516.427 24.291.732

2021-07-07 2021-07-02 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share S - Sale -150.805 311.210 -32,64 20,75 -3.129.204 6.457.608

2021-07-07 2021-07-02 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share S - Sale -928.739 1.963.646 -32,11 20,75 -19.271.334 40.745.654

2021-07-07 2021-07-02 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share S - Sale -1.106.478 2.696.674 -29,09 20,75 -22.959.418 55.955.986

2021-07-06 2021-07-01 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 27.458 208.538 15,16 47,00 1.290.526 9.801.286

2021-07-06 2021-07-01 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 211.711 1.229.017 20,81 47,00 9.950.417 57.763.799

2021-07-06 2021-07-01 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value P - Purchase 304.997 1.664.104 22,44 47,00 14.334.859 78.212.888

2021-07-06 2021-07-06 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 16.980 149.480 12,82 15,25 258.945 2.279.570

2021-07-06 2021-07-06 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 106.627 917.803 13,14 15,25 1.626.062 13.996.496

2021-07-06 2021-07-06 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 146.116 1.259.873 13,12 15,25 2.228.269 19.213.063

2021-07-06 2021-07-01 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 20.018 132.500 17,80 15,65 313.282 2.073.625

2021-07-06 2021-07-01 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 124.804 811.176 18,18 15,65 1.953.183 12.694.904

2021-07-06 2021-07-01 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 172.457 1.113.757 18,32 15,65 2.698.952 17.430.297

2021-06-21 2021-06-16 4 KYMR Kymera Therapeutics, Inc.
Stock Option (Right to Buy) A - Award 20.063 20.063

2021-05-26 2021-03-31 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value J - Other 99.556 99.556

2021-05-25 2021-05-24 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 129 112.482 0,11 15,90 2.050 1.787.924

2021-05-25 2021-05-24 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 513 686.372 0,07 15,90 8.154 10.910.020

2021-05-25 2021-05-24 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 719 941.300 0,08 15,90 11.429 14.962.152

2021-05-25 2021-05-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 7.592 112.353 7,25 15,94 121.032 1.791.132

2021-05-25 2021-05-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 48.152 685.859 7,55 15,94 767.639 10.933.964

2021-05-25 2021-05-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 66.242 940.581 7,58 15,94 1.056.030 14.994.742

2021-05-21 2021-05-19 4 XOMA XOMA Corp
Non-Qualified Stock Option (right to buy) A - Award 5.101 5.101

2021-05-20 2021-05-19 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 1.115 104.761 1,08 15,88 17.711 1.664.055

2021-05-20 2021-05-19 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 6.962 637.707 1,10 15,88 110.586 10.129.529

2021-05-20 2021-05-19 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 9.191 874.339 1,06 15,88 145.993 13.888.263

2021-05-20 2021-05-18 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 11.946 103.646 13,03 16,65 198.901 1.725.706

2021-05-20 2021-05-18 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 75.640 630.745 13,63 16,65 1.259.406 10.501.904

2021-05-20 2021-05-18 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 103.611 865.148 13,61 16,65 1.725.123 14.404.714

2021-05-17 2021-04-26 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 1.747 88.226 2,02 14,90 26.032 1.314.647

2021-05-17 2021-04-26 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 10.876 532.384 2,09 14,90 162.062 7.933.001

2021-05-17 2021-04-26 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 14.790 729.732 2,07 14,90 220.384 10.873.664

2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 6.141 86.479 7,64 15,93 97.817 1.377.481

2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 62.948 80.338 361,98 17,00 1.070.116 1.365.746

2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 38.858 521.508 8,05 15,93 618.950 8.306.840

2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 398.300 482.650 472,20 17,00 6.771.100 8.205.050

2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 53.303 714.942 8,06 15,93 849.037 11.387.954

2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 546.346 661.639 473,88 17,00 9.287.882 11.247.863

2021-05-17 2021-05-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 3.474 91.700 3,94 14,26 49.544 1.307.780

2021-05-17 2021-05-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 22.721 555.105 4,27 14,26 324.036 7.916.630

2021-05-17 2021-05-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value P - Purchase 31.805 761.537 4,36 14,26 453.587 10.860.660

2021-04-27 2021-04-26 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value A - Award 1.747 88.226 2,02 14,90 26.032 1.314.647

2021-04-27 2021-04-26 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value A - Award 10.876 532.384 2,09 14,90 162.062 7.933.001

2021-04-27 2021-04-26 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value A - Award 14.790 729.732 2,07 14,90 220.384 10.873.664

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series B Convertible Preferred Stock C - Conversion -134.515 0 -100,00

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock C - Conversion -152.176 0 -100,00

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock C - Conversion -17.390 152.176 -10,26

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series B Convertible Preferred Stock C - Conversion -837.397 0 -100,00

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock C - Conversion -553.359 0 -100,00

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock C - Conversion -84.350 553.359 -13,23

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series B Convertible Preferred Stock C - Conversion -1.068.554 0 -100,00

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock C - Conversion -832.261 0 -100,00

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock C - Conversion -115.293 832.261 -12,17

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value C - Conversion 134.515 286.691 88,39

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value C - Conversion 152.176 152.176

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value A - Award 6.141 86.479 7,64 15,93 97.817 1.377.481

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value A - Award 62.948 80.338 361,98 17,00 1.070.116 1.365.746

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value C - Conversion 17.390 17.390

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value C - Conversion 837.397 1.390.756 151,33

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value C - Conversion 553.359 553.359

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value A - Award 38.858 521.508 8,05 15,93 618.950 8.306.840

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value A - Award 398.300 482.650 472,20 17,00 6.771.100 8.205.050

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value C - Conversion 84.350 84.350

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value C - Conversion 1.068.554 1.900.815 128,39

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value C - Conversion 832.261 832.261

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value A - Award 53.303 714.942 8,06 15,93 849.037 11.387.954

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value A - Award 546.346 661.639 473,88 17,00 9.287.882 11.247.863

2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value C - Conversion 115.293 115.293

2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock P - Purchase 17 17 25.000,00 425.000 425.000

2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock P - Purchase 239 239 25.000,00 5.975.000 5.975.000

2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock P - Purchase 344 344 25.000,00 8.600.000 8.600.000

2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 P - Purchase 5.171 488.879 1,07 2,50 12.928 1.222.198

2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 P - Purchase 950.016 3.059.296 45,04 2,50 2.375.040 7.648.240

2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 P - Purchase 1.044.813 4.085.933 34,36 2,50 2.612.032 10.214.832

2021-04-02 2021-03-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share S - Sale -81.903 149.975 -35,32 38,36 -3.141.799 5.753.041

2021-04-02 2021-03-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share S - Sale -84.250 75.287 -52,81 38,36 -3.231.830 2.888.009

2021-04-02 2021-03-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share S - Sale -205.807 1.544.897 -11,76 38,36 -7.894.757 59.262.249

2021-04-02 2021-03-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share S - Sale -279.740 1.760.384 -13,71 38,36 -10.730.826 67.528.330

2021-04-01 2021-03-30 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 26.894 462.015 6,18 19,75 531.156 9.124.796

2021-04-01 2021-03-30 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 108.106 2.892.385 3,88 19,75 2.135.094 57.124.604

2021-04-01 2021-03-30 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 165.000 3.803.152 4,54 19,75 3.258.750 75.112.252

2021-03-24 2021-03-22 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 7.744 435.121 1,81 22,75 176.176 9.899.003

2021-03-24 2021-03-22 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 71.756 3.638.152 2,01 22,75 1.632.449 82.767.958

2021-03-18 2021-03-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 1.171 427.377 0,27 23,00 26.933 9.829.500

2021-03-18 2021-03-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 195.768 2.784.279 7,56 23,00 4.502.586 64.037.303

2021-03-18 2021-03-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 53.061 3.566.396 1,51 23,00 1.220.382 82.025.681

2021-03-12 2021-03-10 4 CTIC CTI BIOPHARMA CORP
Stock Option (Right to Buy) A - Award 80.000 80.000

2021-03-08 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share 3.372.098

2021-03-08 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share 2.484.643

2021-03-08 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share 405.344

2021-02-16 2021-02-11 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -152.127 534.847 -22,14 5,37 -816.709 2.871.380

2021-02-16 2021-02-11 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -892.467 3.279.831 -21,39 5,37 -4.791.298 17.608.101

2021-02-16 2021-02-11 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -1.215.491 4.448.421 -21,46 5,37 -6.525.485 23.881.793

2021-02-04 2021-02-02 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value S - Sale -4.325 233.150 -1,82 18,00 -77.850 4.196.700

2021-02-04 2021-02-02 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value S - Sale -16.850 1.188.131 -1,40 18,00 -303.300 21.386.358

2021-02-04 2021-02-02 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value S - Sale -25.234 1.642.186 -1,51 18,00 -454.212 29.559.348

2021-01-26 2021-01-22 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -568.019 686.974 -45,26 4,14 -2.350.917 2.843.248

2021-01-26 2021-01-22 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -2.458.838 4.172.298 -37,08 4,14 -10.176.639 17.268.307

2021-01-26 2021-01-22 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -2.821.663 5.663.912 -33,25 4,14 -11.678.299 23.441.799

2021-01-25 2021-01-21 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 43.422 426.206 11,34 24,75 1.074.694 10.548.598

2021-01-25 2021-01-21 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 343.444 2.588.511 15,30 24,75 8.500.239 64.065.647

2021-01-25 2021-01-21 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 457.814 3.513.335 14,98 24,75 11.330.896 86.955.041

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock C - Conversion -1.757 6.758 -20,63

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock C - Conversion -9.169 39.693 -18,77

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock C - Conversion -11.776 52.145 -18,42

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred C - Conversion -35 0 -100,00

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred C - Conversion -203 0 -100,00

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred C - Conversion -273 0 -100,00

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value C - Conversion 97.615 113.152 628,27

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value C - Conversion 1.944 15.537 14,30

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value C - Conversion 509.410 598.624 571,00

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value C - Conversion 11.278 89.214 14,47

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value C - Conversion 654.215 771.780 556,47

2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value C - Conversion 15.166 117.565 14,81

2020-12-28 3 CTMX CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share 2.945.743

2020-12-28 3 CTMX CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share 2.164.406

2020-12-28 3 CTMX CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share 358.450

2020-12-22 2020-12-18 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 45.032 2.245.067 2,05 16,05 722.764 36.033.325

2020-12-22 2020-12-18 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 114.968 3.055.521 3,91 16,05 1.845.236 49.041.112

2020-12-15 2020-12-11 4 XOMA XOMA Corp
8.625% Series A Cumulative Perpetual Preferred Stock P - Purchase 200.000 200.000 25,00 5.000.000 5.000.000

2020-12-11 2020-12-09 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value S - Sale -25.486 463.244 -5,21 18,00 -458.748 8.338.392

2020-12-11 2020-12-09 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value S - Sale -166.194 2.760.185 -5,68 18,00 -2.991.492 49.683.330

2020-12-11 2020-12-09 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value S - Sale -239.274 3.811.271 -5,91 18,00 -4.306.932 68.602.878

2020-12-04 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 4.050.545

2020-12-04 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 2.926.379

2020-12-04 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 488.730

2020-11-20 2020-11-20 4 CYTK CYTOKINETICS INC
Call Option J - Other -93 0 -100,00

2020-11-20 2020-11-20 4 CYTK CYTOKINETICS INC
Call Option J - Other -551 0 -100,00

2020-11-20 2020-11-20 4 CYTK CYTOKINETICS INC
Call Option J - Other -740 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock C - Conversion -73.399 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock C - Conversion -522.403 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock C - Conversion -760.155 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock C - Conversion -101.784 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock C - Conversion -673.281 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock C - Conversion -889.186 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock C - Conversion -185.908 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock C - Conversion -881.156 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock C - Conversion -1.129.404 0 -100,00

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 74.991 436.082 20,77 19,00 1.424.829 8.285.558

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value C - Conversion 73.399 361.091 25,51

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value C - Conversion 101.784 287.692 54,75

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value C - Conversion 185.908 185.908

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 446.425 2.523.265 21,50 19,00 8.482.075 47.942.035

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value C - Conversion 522.403 2.076.840 33,61

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value C - Conversion 673.281 1.554.437 76,41

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value C - Conversion 881.156 881.156

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value P - Purchase 613.918 3.392.663 22,09 19,00 11.664.442 64.460.597

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value C - Conversion 760.155 2.778.745 37,66

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value C - Conversion 889.186 2.018.590 78,73

2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value C - Conversion 1.129.404 1.129.404

2020-11-20 2020-11-18 4 OLMA Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) A - Award 21.520 21.520

2020-11-20 2020-11-18 4 OLMA Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) A - Award 21.520 21.520

2020-11-20 2020-11-18 4 OLMA Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) A - Award 21.520 21.520

2020-11-16 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 3.822.766

2020-11-16 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 2.777.320

2020-11-16 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 465.924

2020-11-13 2020-11-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value S - Sale -502.649 81.263 -86,08 20,19 -10.146.825 1.640.432

2020-11-13 2020-11-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value S - Sale -2.949.477 485.513 -85,87 20,19 -59.540.207 9.800.905

2020-11-13 2020-11-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value S - Sale -3.941.214 670.695 -85,46 20,19 -79.560.105 13.539.119

2020-11-06 2020-11-04 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value P - Purchase 86.090 630.453 15,81 2,60 223.834 1.639.178

2020-11-06 2020-11-04 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value P - Purchase 506.155 3.712.350 15,79 2,60 1.316.003 9.652.110

2020-11-06 2020-11-04 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value P - Purchase 674.492 4.980.812 15,66 2,60 1.753.679 12.950.111

2020-11-06 2020-11-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 2.334 583.912 0,40 4,98 11.633 2.910.217

2020-11-06 2020-11-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 10.436 3.434.990 0,30 4,98 52.013 17.119.990

2020-11-06 2020-11-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 17.230 4.611.909 0,37 4,98 85.874 22.985.754

2020-11-06 2020-11-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 15.355 581.578 2,71 4,88 74.997 2.840.543

2020-11-06 2020-11-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 143.403 3.424.554 4,37 4,88 700.409 16.726.207

2020-11-06 2020-11-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 257.804 4.594.679 5,94 4,88 1.259.166 22.441.331

2020-11-03 2020-10-30 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value P - Purchase 15.472 544.363 2,93 2,75 42.548 1.496.998

2020-11-03 2020-10-30 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value P - Purchase 250.755 3.206.195 8,48 2,75 689.576 8.817.036

2020-11-03 2020-10-30 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value P - Purchase 666.385 4.306.320 18,31 2,75 1.832.559 11.842.380

2020-10-08 2020-10-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 25.107 566.223 4,64 5,04 126.414 2.850.933

2020-10-08 2020-10-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 162.352 3.281.151 5,21 5,04 817.442 16.520.595

2020-10-08 2020-10-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 157.782 4.336.875 3,78 5,04 794.432 21.836.166

2020-10-05 3 NVUS Novus Therapeutics, Inc.
Common Stock 102.400

2020-10-05 3 NVUS Novus Therapeutics, Inc.
Common Stock 77.936

2020-10-05 3 NVUS Novus Therapeutics, Inc.
Common Stock 13.595

2020-09-24 2020-09-22 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 32 541.116 0,01 3,80 122 2.055.537

2020-09-23 2020-09-23 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 7.201 1.750.704 0,41 18,20 131.057 31.862.463

2020-09-23 2020-09-23 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 9.888 2.040.124 0,49 18,20 179.960 37.129.849

2020-09-23 2020-09-22 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 4.991 1.743.503 0,29 18,45 92.062 32.160.133

2020-09-23 2020-09-22 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 6.960 2.030.236 0,34 18,45 128.382 37.449.124

2020-09-23 2020-09-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 10.069 1.738.512 0,58 18,39 185.120 31.962.717

2020-09-23 2020-09-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 12.259 2.023.276 0,61 18,39 225.383 37.198.132

2020-09-17 2020-09-15 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 10.258 382.784 2,75 11,75 120.532 4.497.712

2020-09-17 2020-09-15 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 58.745 2.200.035 2,74 11,75 690.254 25.850.411

2020-09-17 2020-09-15 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 77.751 2.940.553 2,72 11,75 913.574 34.551.498

2020-09-14 2020-09-10 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 12.816 372.526 3,56 11,10 142.235 4.134.368

2020-09-14 2020-09-10 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 76.374 2.141.290 3,70 11,10 847.614 23.764.465

2020-09-14 2020-09-10 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 100.461 2.862.802 3,64 11,10 1.114.936 31.771.949

2020-09-10 2020-09-04 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 3.830 1.728.443 0,22 18,77 71.891 32.443.912

2020-09-10 2020-09-04 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 3.907 2.011.017 0,19 18,77 73.337 37.747.996

2020-09-08 2020-09-03 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 14.339 359.710 4,15 11,17 160.167 4.017.961

2020-09-08 2020-09-03 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 82.740 2.064.916 4,17 11,17 924.206 23.065.112

2020-09-08 2020-09-03 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 104.827 2.762.341 3,94 11,17 1.170.918 30.855.349

2020-09-01 2020-09-01 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 7.672 1.724.613 0,45 18,87 144.741 32.536.721

2020-09-01 2020-09-01 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 9.900 2.007.110 0,50 18,87 186.774 37.866.338

2020-09-01 2020-08-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 6.862 1.716.941 0,40 18,48 126.814 31.730.100

2020-09-01 2020-08-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 9.143 1.997.210 0,46 18,48 168.968 36.909.639

2020-09-01 2020-08-28 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 922 1.710.079 0,05 19,17 17.676 32.785.464

2020-09-01 2020-08-28 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 1.122 1.988.067 0,06 19,17 21.511 38.115.022

2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Series C Preferred Stock C - Conversion -180.686 0 -100,00

2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Series C Preferred Stock C - Conversion -1.000.955 0 -100,00

2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Series C Preferred Stock C - Conversion -1.336.390 0 -100,00

2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value A - Award 67.791 181.081 59,84 20,00 1.355.820 3.621.620

2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value C - Conversion 113.290 113.290

2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value A - Award 389.709 1.017.307 62,10 20,00 7.794.180 20.346.140

2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value C - Conversion 627.598 627.598

2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value A - Award 521.193 1.359.109 62,20 20,00 10.423.860 27.182.180

2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value C - Conversion 837.916 837.916

2020-08-25 2020-08-20 4 KYMR Kymera Therapeutics, Inc.
Stock Option (Right to Buy) A - Award -40.127 40.127 -50,00

2020-08-25 2020-08-25 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 2.244 1.709.157 0,13 19,74 44.308 33.747.305

2020-08-25 2020-08-25 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 3.443 1.986.945 0,17 19,74 67.982 39.232.229

2020-08-25 2020-08-24 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 5.179 1.706.913 0,30 19,31 100.003 32.959.295

2020-08-25 2020-08-24 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 6.504 1.983.502 0,33 19,31 125.588 38.300.035

2020-08-25 2020-08-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 1.607 1.701.734 0,09 19,32 31.050 32.880.224

2020-08-25 2020-08-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 9.198 1.976.998 0,47 19,32 177.720 38.198.765

2020-08-20 2020-08-18 4 PRNB Principia Biopharma Inc.
Call Option (Right to Buy) P - Purchase 158 3.547 4,66 35,79 5.655 126.947

2020-08-20 2020-08-18 4 PRNB Principia Biopharma Inc.
Call Option (Right to Buy) P - Purchase 905 20.390 4,64 35,79 32.390 729.758

2020-08-20 2020-08-18 4 PRNB Principia Biopharma Inc.
Call Option (Right to Buy) P - Purchase 1.205 27.265 4,62 35,79 43.127 975.814

2020-08-20 2020-08-20 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 1.772 1.967.800 0,09 19,12 33.881 37.624.336

2020-08-20 2020-08-19 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 3.496 1.966.028 0,18 19,70 68.877 38.733.897

2020-08-20 2020-08-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 895 1.962.532 0,05 19,27 17.246 37.816.814

2020-08-14 2020-08-14 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 21.922 1.961.637 1,13 18,69 409.810 36.670.842

2020-08-14 2020-08-13 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 1.050 1.939.715 0,05 17,80 18.693 34.533.134

2020-08-14 2020-08-12 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 4.050 1.938.665 0,21 17,34 70.233 33.619.359

2020-07-02 2020-06-30 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 81 237.475 0,03 13,32 1.079 3.162.312

2020-07-02 2020-06-30 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 929 1.204.981 0,08 13,32 12.371 16.046.009

2020-07-02 2020-06-30 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 1.521 1.667.420 0,09 13,32 20.254 22.204.032

2020-06-22 2020-06-22 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 1.354 237.394 0,57 13,93 18.868 3.308.014

2020-06-22 2020-06-22 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 7.854 1.204.052 0,66 13,93 109.443 16.778.103

2020-06-22 2020-06-22 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 10.524 1.665.899 0,64 13,93 146.649 23.213.803

2020-06-22 2020-06-19 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 6.769 236.040 2,95 14,39 97.403 3.396.498

2020-06-22 2020-06-19 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 39.052 1.196.198 3,37 14,39 561.939 17.212.691

2020-06-22 2020-06-19 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 52.443 1.655.375 3,27 14,39 754.629 23.820.019

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.592.281

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 4.146.495

2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 3.218.620

2020-06-10 2020-06-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 6.967 345.371 2,06 15,20 105.898 5.249.639

2020-06-10 2020-06-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 33.321 1.982.176 1,71 15,20 506.479 30.129.075

2020-06-10 2020-06-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 46.966 2.657.514 1,80 15,20 713.883 40.394.213

2020-06-03 2020-06-01 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 94.101 338.404 38,52 14,00 1.317.414 4.737.656

2020-06-03 2020-06-01 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 561.966 1.948.855 40,52 14,00 7.867.524 27.283.970

2020-06-03 2020-06-01 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 806.443 2.610.548 44,70 14,00 11.290.202 36.547.672

2020-05-26 2020-05-21 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value S - Sale -192.250 480.432 -28,58 6,00 -1.153.500 2.882.592

2020-05-26 2020-05-21 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value S - Sale -1.064.332 2.766.561 -27,78 6,00 -6.385.992 16.599.366

2020-05-26 2020-05-21 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value S - Sale -1.027.016 3.712.340 -21,67 6,00 -6.162.096 22.274.040

2020-05-18 2020-05-14 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 4.476 541.084 0,83 4,10 18.352 2.218.444

2020-05-18 2020-05-14 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 39.810 3.118.799 1,29 4,10 163.221 12.787.076

2020-05-18 2020-05-14 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 249.301 4.179.093 6,34 4,10 1.022.134 17.134.281

2020-04-17 2020-04-15 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock C - Conversion -597 0 -100,00

2020-04-17 2020-04-15 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock C - Conversion -656 0 -100,00

2020-04-17 2020-04-15 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share C - Conversion 596.813 1.700.127 54,09 13,00 7.758.569 22.101.651

2020-04-17 2020-04-15 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share C - Conversion 655.959 1.934.615 51,30 13,00 8.527.467 25.149.995

2020-03-27 2020-03-25 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 8.264 1.278.656 0,65 17,20 142.129 21.991.093

2020-03-20 2020-03-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 4.439 1.270.392 0,35 14,52 64.475 18.451.936

2020-03-17 2020-03-17 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 8.113 1.265.953 0,64 15,73 127.648 19.918.125

2020-03-17 2020-03-16 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 10.164 1.257.840 0,81 15,73 159.916 19.790.351

2020-03-17 2020-03-13 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 100.000 1.247.676 8,71 18,34 1.834.090 22.883.501

2020-03-04 2020-03-04 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock P - Purchase 12 12

2020-03-04 2020-03-04 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock P - Purchase 87 191 83,65

2020-03-04 2020-03-04 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock P - Purchase 841 1.250 205,62

2020-03-04 2020-03-04 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock P - Purchase 981 1.594 160,03

2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock X - Other 104 104

2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Subscription Rights (right to buy) X - Other -104 0 -100,00

2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock X - Other 409 409

2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Subscription Rights (right to buy) X - Other -409 0 -100,00

2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock X - Other 613 613

2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Subscription Rights (right to buy) X - Other -613 0 -100,00

2020-02-18 2020-02-13 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value S - Sale -74.893 424.419 -15,00 15,79 -1.182.321 6.700.218

2020-02-18 2020-02-13 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value S - Sale -510.793 2.350.829 -17,85 15,79 -8.063.787 37.112.067

2020-02-18 2020-02-13 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value S - Sale -486.344 3.131.432 -13,44 15,79 -7.677.815 49.435.291

2020-01-21 2020-01-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 19.727 244.303 8,78 16,15 318.591 3.945.493

2020-01-21 2020-01-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 112.561 1.386.889 8,83 16,15 1.817.860 22.398.257

2020-01-21 2020-01-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 146.442 1.804.105 8,83 16,15 2.365.038 29.136.296

2020-01-15 2020-01-13 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 5.406 224.576 2,47 14,98 80.973 3.363.789

2020-01-15 2020-01-13 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 25.108 1.274.328 2,01 14,98 376.078 19.087.395

2020-01-15 2020-01-13 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share P - Purchase 53.448 1.657.663 3,33 14,98 800.566 24.829.139

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.676.820

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.321.825

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 3.291.775

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.676.820

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.321.825

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 3.291.775

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.676.820

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.321.825

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 3.291.775

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.676.820

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.321.825

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 3.291.775

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.676.820

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.321.825

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 3.291.775

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.676.820

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.321.825

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 3.291.775

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.676.820

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.321.825

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 3.291.775

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.676.820

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.321.825

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 3.291.775

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.676.820

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 4.321.825

2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 3.291.775

2019-12-26 2019-12-20 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 32.606 536.608 6,47 4,05 132.054 2.173.262

2019-12-26 2019-12-20 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 201.096 3.078.989 6,99 4,05 814.439 12.469.905

2019-12-26 2019-12-20 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 281.318 3.929.792 7,71 4,05 1.139.338 15.915.658

2019-12-20 2019-12-19 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 165.961 1.103.314 17,71 22,00 3.651.142 24.272.908

2019-12-20 2019-12-19 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 207.234 1.147.676 22,04 22,00 4.559.148 25.248.872

2019-12-20 2019-12-18 4 XOMA XOMA Corp
Subscription Rights (right to buy) X - Other -35.888 0 -100,00

2019-12-20 2019-12-18 4 XOMA XOMA Corp
Subscription Rights (right to buy) X - Other -190.899 0 -100,00

2019-12-20 2019-12-18 4 XOMA XOMA Corp
Subscription Rights (right to buy) X - Other -245.481 0 -100,00

2019-12-20 2019-12-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share X - Other 35.888 159.537 29,02 22,00 789.536 3.509.814

2019-12-20 2019-12-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share X - Other 190.899 937.353 25,57 22,00 4.199.778 20.621.766

2019-12-20 2019-12-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share X - Other 245.481 940.442 35,32 22,00 5.400.582 20.689.724

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 10.080.782

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 9.353.356

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 7.112.414

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 10.080.782

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 9.353.356

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 7.112.414

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 10.080.782

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 9.353.356

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 7.112.414

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 10.080.782

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 9.353.356

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 7.112.414

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 10.080.782

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 9.353.356

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 7.112.414

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 10.080.782

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 9.353.356

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 7.112.414

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 10.080.782

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 9.353.356

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 7.112.414

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 10.080.782

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 9.353.356

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 7.112.414

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 10.080.782

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 9.353.356

2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 7.112.414

2019-12-12 2019-12-11 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value P - Purchase 8.506 499.312 1,73 9,52 80.935 4.750.954

2019-12-12 2019-12-11 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value P - Purchase 49.804 2.861.622 1,77 9,52 473.885 27.228.333

2019-12-12 2019-12-11 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value P - Purchase 60.103 3.617.776 1,69 9,52 571.880 34.423.139

2019-12-12 2019-12-10 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value P - Purchase 15.030 490.806 3,16 9,40 141.282 4.613.576

2019-12-12 2019-12-10 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value P - Purchase 95.100 2.811.818 3,50 9,40 893.940 26.431.089

2019-12-12 2019-12-10 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value P - Purchase 113.529 3.557.673 3,30 9,40 1.067.173 33.442.126

2019-12-11 2019-12-09 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 2.397 504.002 0,48 4,02 9.630 2.024.828

2019-12-11 2019-12-09 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 18.729 2.877.893 0,66 4,02 75.244 11.561.935

2019-12-11 2019-12-09 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 113.874 3.648.474 3,22 4,02 457.489 14.657.744

2019-11-26 2019-11-22 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 81.857 501.605 19,50 3,40 278.322 1.705.507

2019-11-26 2019-11-22 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 462.056 2.859.164 19,28 3,40 1.571.037 9.721.444

2019-11-26 2019-11-22 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 576.097 3.534.600 19,47 3,40 1.958.787 12.017.993

2019-11-22 2019-11-20 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 14.151 672.682 2,15 3,91 55.353 2.631.263

2019-11-22 2019-11-20 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 79.285 3.830.893 2,11 3,91 310.131 14.984.921

2019-11-22 2019-11-20 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 98.518 4.739.356 2,12 3,91 385.363 18.538.465

2019-11-18 2019-11-14 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 11.105 658.531 1,72 3,37 37.424 2.219.249

2019-11-18 2019-11-14 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 45.888 3.751.608 1,24 3,37 154.643 12.642.919

2019-11-18 2019-11-14 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 71.495 4.640.838 1,56 3,37 240.938 15.639.624

2019-11-07 2019-11-05 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 70.921 419.748 20,33 4,00 283.684 1.678.992

2019-11-07 2019-11-05 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 400.470 2.397.108 20,06 4,00 1.601.880 9.588.432

2019-11-07 2019-11-05 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 496.721 2.958.503 20,18 4,00 1.986.884 11.834.012

2019-10-31 2019-10-30 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 57.868 647.426 9,82 2,70 156.244 1.748.050

2019-10-31 2019-10-30 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 331.048 3.705.720 9,81 2,70 893.830 10.005.444

2019-10-31 2019-10-30 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 408.592 4.569.343 9,82 2,70 1.103.198 12.337.226

2019-10-31 2019-10-29 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 116.552 589.558 24,64 2,60 303.035 1.532.851

2019-10-31 2019-10-29 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 610.052 3.374.672 22,07 2,60 1.586.135 8.774.147

2019-10-31 2019-10-29 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value P - Purchase 872.373 4.160.751 26,53 2,60 2.268.170 10.817.953

2019-10-31 2019-10-31 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 504 348.827 0,14 3,85 1.940 1.342.844

2019-10-31 2019-10-31 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 2.913 1.996.638 0,15 3,85 11.214 7.686.258

2019-10-31 2019-10-31 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 3.416 2.461.782 0,14 3,85 13.150 9.476.876

2019-10-31 2019-10-30 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 1.456 348.323 0,42 3,89 5.667 1.355.708

2019-10-31 2019-10-30 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 8.236 1.993.725 0,41 3,89 32.055 7.759.777

2019-10-31 2019-10-30 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 10.389 2.458.366 0,42 3,89 40.435 9.568.206

2019-10-31 2019-10-29 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 240 346.867 0,07 3,90 935 1.351.706

2019-10-31 2019-10-29 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 1.133 1.985.489 0,06 3,90 4.415 7.737.252

2019-10-31 2019-10-29 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 1.027 2.447.977 0,04 3,90 4.002 9.539.522

2019-10-25 2019-10-25 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 2.155 346.627 0,63 3,75 8.075 1.298.915

2019-10-25 2019-10-25 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 12.899 1.984.356 0,65 3,75 48.336 7.435.977

2019-10-25 2019-10-25 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 15.728 2.446.950 0,65 3,75 58.938 9.169.456

2019-10-25 2019-10-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 1.629 344.472 0,48 3,74 6.100 1.289.944

2019-10-25 2019-10-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 57.723 1.971.457 3,02 3,74 216.155 7.382.515

2019-10-25 2019-10-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 76.036 2.431.222 3,23 3,74 284.732 9.104.197

2019-10-25 2019-10-23 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 3.200 2.355.186 0,14 3,75 11.986 8.821.349

2019-10-08 2019-10-08 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 4.689 342.843 1,39 3,68 17.270 1.262.691

2019-10-08 2019-10-08 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 24.716 1.913.734 1,31 3,68 91.029 7.048.282

2019-10-08 2019-10-08 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 31.007 2.351.986 1,34 3,68 114.199 8.662.364

2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 24.425 338.154 7,79 3,75 91.594 1.268.078

2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 14.242 313.729 4,76 3,75 53.382 1.175.919

2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 138.609 1.889.018 7,92 3,75 519.784 7.083.818

2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 80.821 1.750.409 4,84 3,75 302.933 6.560.883

2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 168.640 2.320.979 7,84 3,75 632.400 8.703.671

2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 98.333 2.152.339 4,79 3,75 368.572 8.067.397

2019-10-08 2019-10-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 991 299.487 0,33 3,74 3.704 1.119.333

2019-10-08 2019-10-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 7.314 1.669.588 0,44 3,74 27.336 6.240.085

2019-10-08 2019-10-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value P - Purchase 7.695 2.054.006 0,38 3,74 28.760 7.676.847

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 6.053.392

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 5.669.355

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 4.305.577

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 6.053.392

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 5.669.355

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 4.305.577

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 6.053.392

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 5.669.355

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 4.305.577

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 6.053.392

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 5.669.355

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 4.305.577

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 6.053.392

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 5.669.355

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 4.305.577

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 6.053.392

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 5.669.355

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 4.305.577

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 6.053.392

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 5.669.355

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 4.305.577

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 6.053.392

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 5.669.355

2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 4.305.577

2019-09-10 2019-09-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -1.128 314.139 -0,36 4,50 -5.075 1.413.437

2019-09-10 2019-09-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -25.720 2.233.074 -1,14 4,50 -115.725 10.047.493

2019-09-10 2019-09-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -23.152 2.385.055 -0,96 4,50 -104.170 10.731.316

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.390.475

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.241.062

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.297.535

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.390.475

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.241.062

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.297.535

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.390.475

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.241.062

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.297.535

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.390.475

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.241.062

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.297.535

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.390.475

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.241.062

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.297.535

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.390.475

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.241.062

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.297.535

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.390.475

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.241.062

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.297.535

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.390.475

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.241.062

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.297.535

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.390.475

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.241.062

2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.297.535

2019-09-09 2019-09-05 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value P - Purchase 124.956 528.891 30,93 3,18 397.610 1.682.931

2019-09-09 2019-09-05 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value P - Purchase 689.834 2.955.440 30,45 3,18 2.195.052 9.404.210

2019-09-09 2019-09-05 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value P - Purchase 853.956 3.639.935 30,65 3,18 2.717.288 11.582.273

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 8.241.499

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 7.721.126

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 5.859.455

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 8.241.499

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 7.721.126

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 5.859.455

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 8.241.499

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 7.721.126

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 5.859.455

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 8.241.499

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 7.721.126

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 5.859.455

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 8.241.499

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 7.721.126

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 5.859.455

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 8.241.499

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 7.721.126

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 5.859.455

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 8.241.499

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 7.721.126

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 5.859.455

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 8.241.499

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 7.721.126

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 5.859.455

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 8.241.499

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 7.721.126

2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 5.859.455

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.814.382

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.290.624

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 6.999.010

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.814.382

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.290.624

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 6.999.010

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.814.382

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.290.624

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 6.999.010

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.814.382

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.290.624

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 6.999.010

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.814.382

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.290.624

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 6.999.010

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.814.382

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.290.624

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 6.999.010

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.814.382

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.290.624

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 6.999.010

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.814.382

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.290.624

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 6.999.010

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.814.382

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 9.290.624

2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 6.999.010

2019-06-12 2019-06-10 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -29.450 169.589 -14,80 10,70 -315.230 1.815.264

2019-06-12 2019-06-10 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -158.583 952.859 -14,27 10,70 -1.697.457 10.199.307

2019-06-12 2019-06-10 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -198.256 1.178.904 -14,40 10,70 -2.122.112 12.618.871

2019-05-14 2019-05-14 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 13.816 746.454 1,89 14,74 203.664 11.003.628

2019-05-14 2019-05-13 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 3.797 732.638 0,52 14,36 54.526 10.520.975

2019-05-14 2019-05-10 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 10.300 728.841 1,43 14,57 150.037 10.616.808

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 4.064.801

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 3.799.083

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 2.886.680

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 4.064.801

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 3.799.083

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 2.886.680

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 4.064.801

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 3.799.083

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 2.886.680

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 4.064.801

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 3.799.083

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 2.886.680

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 4.064.801

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 3.799.083

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 2.886.680

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 4.064.801

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 3.799.083

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 2.886.680

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 4.064.801

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 3.799.083

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 2.886.680

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 4.064.801

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 3.799.083

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 2.886.680

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 4.064.801

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 3.799.083

2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 2.886.680

2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value J - Other 284 284

2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value J - Other 2.143 2.143

2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value J - Other 2.573 2.573

2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value J - Other -284.000 141.346 -66,77

2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value J - Other -2.143.000 772.324 -73,51

2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value J - Other -2.573.000 978.200 -72,45

2018-12-19 2018-12-18 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock X - Other 372 597 165,47 13.000,00 4.836.000 7.758.569

2018-12-19 2018-12-18 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock X - Other 311 656 89,96 13.000,00 4.038.398 8.527.467

2018-12-19 2018-12-17 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 25.000 718.541 3,60 14,19 354.792 10.197.318

2018-12-19 2018-12-14 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock X - Other 225 225 13.000,00 2.922.569 2.922.569

2018-12-19 2018-12-14 4 XOMA XOMA Corp
Subscription Rights X - Other -225 0 -100,00

2018-12-19 2018-12-14 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock X - Other 345 345 13.000,00 4.489.069 4.489.069

2018-12-19 2018-12-14 4 XOMA XOMA Corp
Subscription Rights X - Other -345 0 -100,00

2018-12-17 2018-12-13 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 120.539 6.631.136 1,85 1,20 144.587 7.954.048

2018-12-17 2018-12-13 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 54.461 8.485.575 0,65 1,20 65.326 10.178.447

2018-12-13 2018-12-13 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 24.253 693.541 3,62 14,41 349.525 9.995.035

2018-12-13 2018-12-12 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 2.810 669.288 0,42 14,75 41.448 9.871.998

2018-12-13 2018-12-11 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 9.400 666.478 1,43 14,50 136.270 9.661.798

2018-12-10 2018-12-10 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 18.081 657.078 2,83 14,54 262.972 9.556.608

2018-12-10 2018-12-07 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 32.015 638.997 5,27 14,77 472.778 9.436.324

2018-12-10 2018-12-06 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 10.927 606.982 1,83 14,80 161.698 8.982.120

2018-12-04 2018-12-04 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 4.171 596.055 0,70 14,99 62.515 8.933.672

2018-12-04 2018-12-03 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 806 591.884 0,14 14,90 12.009 8.819.072

2018-12-04 2018-11-30 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 4.823 591.078 0,82 14,85 71.615 8.776.681

2018-12-04 2018-12-04 4 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value S - Sale -89.948 370.391 -19,54 1,83 -164.929 679.149

2018-12-04 2018-12-04 4 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value S - Sale -382.017 1.942.764 -16,43 1,83 -700.466 3.562.252

2018-12-04 2018-12-04 4 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value S - Sale -430.035 2.502.758 -14,66 1,83 -788.512 4.589.057

2018-11-30 2018-11-28 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 100.000 6.510.597 1,56 1,30 130.000 8.463.776

2018-11-29 2018-11-29 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 10.016 586.255 1,74 14,93 149.543 8.753.022

2018-11-29 2018-11-28 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 8.288 576.239 1,46 15,11 125.262 8.709.046

2018-11-29 2018-11-27 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 11.396 567.951 2,05 15,24 173.680 8.655.800

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 10.443.070

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 9.807.194

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.317.216

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 10.443.070

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 9.807.194

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.317.216

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 10.443.070

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 9.807.194

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.317.216

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 10.443.070

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 9.807.194

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.317.216

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 10.443.070

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 9.807.194

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.317.216

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 10.443.070

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 9.807.194

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.317.216

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 10.443.070

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 9.807.194

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.317.216

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 10.443.070

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 9.807.194

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.317.216

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 10.443.070

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 9.807.194

2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.317.216

2018-11-21 2018-11-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 25.000 556.555 4,70 15,00 374.892 8.345.932

2018-11-21 2018-11-20 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 37.482 531.555 7,59 13,68 512.701 7.270.928

2018-11-21 2018-11-19 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 9.771 494.073 2,02 13,93 136.064 6.880.115

2018-11-21 2018-11-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 581 1.254.993 0,05 1,35 784 1.694.241

2018-11-21 2018-11-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 4.119 8.431.114 0,05 1,35 5.561 11.382.004

2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 5.573 1.254.412 0,45 1,35 7.524 1.693.456

2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 38.001 6.410.597 0,60 1,35 51.301 8.654.306

2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 50.044 8.426.995 0,60 1,35 67.559 11.376.443

2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 81.648 1.248.839 7,00 1,37 111.841 1.710.660

2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 556.709 6.372.596 9,57 1,37 762.580 8.729.182

2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 733.151 8.376.951 9,59 1,37 1.004.270 11.474.747

2018-11-19 2018-11-16 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 10.849 484.302 2,29 13,82 149.986 6.695.427

2018-11-19 2018-11-15 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share P - Purchase 21.141 473.453 4,67 13,31 281.361 6.301.091

2018-11-15 2018-11-15 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 39.074 5.815.887 0,68 1,35 52.750 7.851.447

2018-11-15 2018-11-15 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 52.400 7.643.800 0,69 1,35 70.740 10.319.130

2018-11-15 2018-11-14 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 92.960 5.776.813 1,64 1,34 124.566 7.740.929

2018-11-15 2018-11-14 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 117.290 7.591.400 1,57 1,34 157.169 10.172.476

2018-11-15 2018-11-13 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 562.754 5.683.853 10,99 1,35 759.718 7.673.202

2018-11-15 2018-11-13 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 41.454 7.474.110 0,56 1,35 55.963 10.090.048

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.650.706

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.042.694

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 6.178.252

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.650.706

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.042.694

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 6.178.252

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.650.706

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.042.694

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 6.178.252

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.650.706

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.042.694

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 6.178.252

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.650.706

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.042.694

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 6.178.252

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.650.706

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.042.694

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 6.178.252

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.650.706

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.042.694

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 6.178.252

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.650.706

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.042.694

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 6.178.252

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.650.706

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 8.042.694

2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 6.178.252

2018-06-21 2018-06-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 36.825 1.167.191 3,26 1,65 60.761 1.925.865

2018-06-21 2018-06-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 158.151 5.121.099 3,19 1,65 260.949 8.449.813

2018-06-21 2018-06-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 230.555 7.432.656 3,20 1,65 380.416 12.263.882

2018-06-21 2018-06-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 179.893 1.130.366 18,93 1,65 296.823 1.865.104

2018-06-21 2018-06-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 1.419.907 4.962.948 40,08 1,65 2.342.847 8.188.864

2018-06-21 2018-06-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 1.916.760 7.202.101 36,27 1,65 3.162.654 11.883.467

2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Warrants J - Other 188.746 188.746

2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Warrants J - Other 705.863 705.863

2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Warrants J - Other 1.105.391 1.105.391

2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share J - Other -188.746 85.038 -68,94

2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share J - Other -705.863 318.021 -68,94

2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share J - Other -1.105.391 498.025 -68,94

2018-06-01 2018-05-30 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share S - Sale -175.813 771.305 -18,56 5,00 -879.083 3.856.602

2018-06-01 2018-05-30 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share S - Sale -312.266 3.186.044 -8,93 5,00 -1.561.361 15.930.539

2018-06-01 2018-05-30 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share S - Sale -547.860 4.682.669 -10,47 5,00 -2.739.355 23.413.813

2018-04-20 2018-04-18 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share S - Sale -217.256 947.118 -18,66 3,10 -673.494 2.936.066

2018-04-20 2018-04-18 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share S - Sale -808.449 3.498.310 -18,77 3,10 -2.506.192 10.844.761

2018-04-20 2018-04-18 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share S - Sale -1.204.668 5.230.529 -18,72 3,10 -3.734.471 16.214.640

2018-04-11 2018-04-10 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 97.453 950.473 11,42 2,00 194.906 1.900.946

2018-04-11 2018-04-10 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 365.682 3.543.041 11,51 2,00 731.364 7.086.082

2018-04-11 2018-04-10 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 546.865 5.285.341 11,54 2,00 1.093.730 10.570.682

2018-04-11 2018-04-09 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 62.437 853.020 7,90 1,90 118.630 1.620.738

2018-04-11 2018-04-09 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 208.872 3.177.359 7,04 1,90 396.857 6.036.982

2018-04-11 2018-04-09 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 228.691 4.738.476 5,07 1,90 434.513 9.003.104

2018-04-06 2018-04-04 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share S - Sale -214.336 1.164.374 -15,55 2,90 -621.574 3.376.685

2018-04-06 2018-04-04 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share S - Sale -817.611 4.306.759 -15,96 2,90 -2.371.072 12.489.601

2018-04-06 2018-04-04 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share S - Sale -1.269.634 6.435.197 -16,48 2,90 -3.681.939 18.662.071

2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares J - Other 238.000 238.000

2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares J - Other 861.000 861.000

2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares J - Other 1.338.000 1.338.000

2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Common Shares, no par value per share J - Other -238.000 59.464 -80,01

2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Common Shares, no par value per share J - Other -861.000 216.694 -79,89

2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Common Shares, no par value per share J - Other -1.338.000 336.468 -79,91

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series O Preferred Stock A - Award 2.280 2.280

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series O Preferred Stock A - Award 1.024 1.024

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series O Preferred Stock A - Award 3.640 3.640

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series O Preferred Stock A - Award 5.631 5.631

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series N Preferred Stock D - Sale to Issuer -49 0 -100,00

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series N Preferred Stock D - Sale to Issuer -48 0 -100,00

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series N Preferred Stock D - Sale to Issuer -197 0 -100,00

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series N Preferred Stock D - Sale to Issuer -281 0 -100,00

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 P - Purchase 699.225 1.295.582 117,25 3,00 2.097.675 3.886.746

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 P - Purchase 483.708 483.708 3,00 1.451.124 1.451.124

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 P - Purchase 2.109.280 2.109.280 3,00 6.327.840 6.327.840

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 P - Purchase 3.041.120 3.041.120 3,00 9.123.360 9.123.360

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 D - Sale to Issuer -1.487.294 596.357 -71,38

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 D - Sale to Issuer -651.074 0 -100,00

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 D - Sale to Issuer -2.295.083 0 -100,00

2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 D - Sale to Issuer -3.566.549 0 -100,00

2017-12-21 2017-12-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -169.292 122.496 -58,02 26,65 -4.511.632 3.264.518

2017-12-21 2017-12-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -445.615 632.642 -41,33 26,65 -11.875.640 16.859.909

2017-12-21 2017-12-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value S - Sale -667.949 951.300 -41,25 26,65 -17.800.841 25.352.145

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 4.504.500

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.924.968

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.174.868

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 4.504.500

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.924.968

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.174.868

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 4.504.500

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.924.968

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.174.868

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 4.504.500

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.924.968

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.174.868

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 4.504.500

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.924.968

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.174.868

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 4.504.500

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.924.968

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.174.868

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 4.504.500

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.924.968

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.174.868

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 4.504.500

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.924.968

2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 3.174.868

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 17.248.837

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 15.027.176

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 12.158.047

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 17.248.837

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 15.027.176

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 12.158.047

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 17.248.837

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 15.027.176

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 12.158.047

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 17.248.837

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 15.027.176

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 12.158.047

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 17.248.837

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 15.027.176

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 12.158.047

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 17.248.837

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 15.027.176

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 12.158.047

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 17.248.837

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 15.027.176

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 12.158.047

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 17.248.837

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 15.027.176

2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 12.158.047

2017-10-23 2017-10-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 34.632 291.788 13,47 15,84 548.484 4.621.192

2017-10-23 2017-10-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 135.206 1.078.257 14,34 15,84 2.141.325 17.076.895

2017-10-23 2017-10-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 162.078 1.619.249 11,12 15,84 2.566.910 25.644.856

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 21.912.742

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 19.332.281

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 15.586.621

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 21.912.742

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 19.332.281

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 15.586.621

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 21.912.742

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 19.332.281

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 15.586.621

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 21.912.742

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 19.332.281

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 15.586.621

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 21.912.742

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 19.332.281

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 15.586.621

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 21.912.742

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 19.332.281

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 15.586.621

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 21.912.742

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 19.332.281

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 15.586.621

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 21.912.742

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 19.332.281

2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 15.586.621

2017-10-05 2017-10-04 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 63.042 790.583 8,67 1,28 80.946 1.015.109

2017-10-05 2017-10-04 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 235.326 2.968.487 8,61 1,28 302.159 3.811.537

2017-10-05 2017-10-04 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 355.081 4.509.785 8,55 1,28 455.924 5.790.564

2017-10-05 2017-10-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 28.918 727.541 4,14 1,24 35.714 898.513

2017-10-05 2017-10-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 394.078 2.733.161 16,85 1,24 486.686 3.375.454

2017-10-05 2017-10-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 523.601 4.154.704 14,42 1,24 646.647 5.131.059

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 4.114.549

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 3.600.429

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 2.914.534

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 4.114.549

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 3.600.429

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 2.914.534

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 4.114.549

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 3.600.429

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 2.914.534

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 4.114.549

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 3.600.429

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 2.914.534

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 4.114.549

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 3.600.429

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 2.914.534

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 4.114.549

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 3.600.429

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 2.914.534

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 4.114.549

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 3.600.429

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 2.914.534

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 4.114.549

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 3.600.429

2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 2.914.534

2017-08-16 2017-08-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 7.429 1.077.694 0,69 2,41 17.920 2.599.613

2017-08-16 2017-08-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 11.429 1.674.468 0,69 2,41 27.569 4.039.152

2017-08-16 2017-08-14 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 13.337 1.070.265 1,26 2,70 36.058 2.893.568

2017-08-16 2017-08-14 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 28.007 1.663.039 1,71 2,70 75.720 4.496.192

2017-07-18 2017-07-14 4 CAPS Capstone Therapeutics Corp.
Common Stock, $0.0005 par value S - Sale -105.713 890.487 -10,61 0,06 -6.343 53.429

2017-07-18 2017-07-14 4 CAPS Capstone Therapeutics Corp.
Common Stock, $0.0005 par value S - Sale -242.236 1.377.652 -14,95 0,06 -14.534 82.659

2017-07-18 2017-07-14 4 CAPS Capstone Therapeutics Corp.
Common Stock, $0.0005 par value S - Sale -3.993.637 0 -100,00 0,06 -239.618

2017-06-30 2017-06-27 4/A XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 8.496 297.464 2,94 3,04 25.795 903.130

2017-06-30 2017-06-27 4/A XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 30.170 1.056.928 2,94 3,04 91.599 3.208.939

2017-06-30 2017-06-27 4/A XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 46.795 1.635.032 2,95 3,04 142.074 4.964.121

2017-06-29 2017-06-27 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 8.496 297.464 2,94 4,00 33.984 1.189.856

2017-06-29 2017-06-27 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 30.170 1.056.928 2,94 4,00 120.680 4.227.712

2017-06-29 2017-06-27 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 46.795 1.635.032 2,95 4,00 187.180 6.540.128

2017-06-23 2017-06-22 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 854 288.968 0,30 4,00 3.416 1.155.872

2017-06-23 2017-06-22 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 2.884 1.026.758 0,28 4,00 11.536 4.107.032

2017-06-23 2017-06-22 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 4.525 1.588.237 0,29 4,00 18.100 6.352.948

2017-06-23 2017-06-21 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 1.362 288.114 0,47 4,00 5.448 1.152.456

2017-06-23 2017-06-21 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 4.406 1.023.874 0,43 4,00 17.624 4.095.496

2017-06-23 2017-06-21 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 6.380 1.583.712 0,40 4,00 25.520 6.334.848

2017-06-22 2017-06-20 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 1.715 201.811 0,86 2,25 3.859 454.075

2017-06-22 2017-06-20 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 6.359 717.089 0,89 2,25 14.308 1.613.450

2017-06-22 2017-06-20 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 9.732 1.109.258 0,89 2,25 21.897 2.495.830

2017-06-19 2017-06-19 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 357 286.752 0,12 3,85 1.374 1.103.995

2017-06-19 2017-06-19 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 1.271 1.019.468 0,12 3,85 4.893 3.924.952

2017-06-19 2017-06-19 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 1.967 1.577.332 0,12 3,85 7.573 6.072.728

2017-06-19 2017-06-16 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 1.064 286.395 0,37 3,85 4.096 1.102.621

2017-06-19 2017-06-16 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 3.873 1.018.197 0,38 3,85 14.911 3.920.058

2017-06-19 2017-06-16 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 6.097 1.575.365 0,39 3,85 23.473 6.065.155

2017-06-19 2017-06-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 1.160 285.331 0,41 3,84 4.451 1.094.815

2017-06-19 2017-06-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 3.845 1.014.324 0,38 3,84 14.753 3.891.961

2017-06-19 2017-06-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 6.774 1.569.268 0,43 3,84 25.992 6.021.281

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share C - Conversion -536 49 -91,62

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share C - Conversion -513 48 -91,44

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share C - Conversion -2.115 197 -91,48

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share C - Conversion -3.011 281 -91,46

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share P - Purchase 585 585

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share P - Purchase 561 561

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share P - Purchase 2.312 2.312

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share P - Purchase 3.292 3.292

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share C - Conversion 357.333 2.083.651 20,70

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share C - Conversion 342.000 651.074 110,65

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share C - Conversion 1.410.000 2.295.083 159,31

2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share C - Conversion 2.007.333 3.566.549 128,74

2017-06-08 2017-06-07 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 20.594 284.171 7,81 3,85 79.312 1.094.399

2017-06-08 2017-06-07 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 73.749 1.010.479 7,87 3,85 284.022 3.891.557

2017-06-08 2017-06-07 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 113.446 1.562.494 7,83 3,85 436.903 6.017.477

2017-06-08 2017-06-06 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 913 263.577 0,35 3,75 3.424 988.414

2017-06-08 2017-06-06 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 53.260 936.730 6,03 3,75 199.725 3.512.738

2017-06-08 2017-06-06 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share P - Purchase 96.736 1.449.048 7,15 3,75 362.760 5.433.930

2017-06-07 2017-06-07 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 3.673 200.096 1,87 2,28 8.379 456.479

2017-06-07 2017-06-07 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 13.046 710.730 1,87 2,28 29.762 1.621.388

2017-06-07 2017-06-07 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 20.181 1.099.526 1,87 2,28 46.039 2.508.349

2017-06-07 2017-06-05 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 3.920 196.423 2,04 2,29 8.979 449.927

2017-06-07 2017-06-05 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 12.624 697.684 1,84 2,29 28.917 1.598.115

2017-06-07 2017-06-05 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 19.206 1.079.345 1,81 2,29 43.993 2.472.348

2017-06-01 2017-05-31 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 2.727 192.503 1,44 2,25 6.128 432.554

2017-06-01 2017-05-31 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 10.023 685.060 1,48 2,25 22.522 1.539.330

2017-06-01 2017-05-31 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 15.350 1.060.139 1,47 2,25 34.491 2.382.132

2017-06-01 2017-05-30 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 1.805 189.776 0,96 2,30 4.144 435.669

2017-06-01 2017-05-30 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 6.903 675.037 1,03 2,30 15.847 1.549.682

2017-06-01 2017-05-30 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 10.192 1.044.789 0,99 2,30 23.398 2.398.522

2017-05-19 2017-05-19 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 1.124 187.971 0,60 2,30 2.585 432.333

2017-05-19 2017-05-19 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 4.223 668.134 0,64 2,30 9.713 1.536.708

2017-05-19 2017-05-19 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 6.253 1.034.597 0,61 2,30 14.382 2.379.573

2017-05-19 2017-05-18 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 2.909 186.847 1,58 2,30 6.690 429.711

2017-05-19 2017-05-18 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 10.541 663.911 1,61 2,30 24.242 1.526.863

2017-05-19 2017-05-18 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 16.436 1.028.344 1,62 2,30 37.800 2.364.986

2017-05-19 2017-05-17 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 5.510 183.938 3,09 2,30 12.666 422.818

2017-05-19 2017-05-17 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 6.897 653.370 1,07 2,30 15.854 1.501.902

2017-05-19 2017-05-17 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 24.965 1.011.908 2,53 2,30 57.387 2.326.073

2017-05-11 2017-05-11 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 675 178.428 0,38 2,34 1.581 418.039

2017-05-11 2017-05-11 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 2.565 646.473 0,40 2,34 6.010 1.514.622

2017-05-11 2017-05-11 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 3.794 986.943 0,39 2,34 8.889 2.312.309

2017-05-11 2017-05-10 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 6.217 177.753 3,62 2,35 14.583 416.955

2017-05-11 2017-05-10 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 22.092 643.908 3,55 2,35 51.821 1.510.415

2017-05-11 2017-05-10 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 33.691 983.149 3,55 2,35 79.029 2.306.173

2017-05-11 2017-05-09 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 3.929 171.536 2,34 2,29 8.989 392.457

2017-05-11 2017-05-09 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 14.274 621.816 2,35 2,29 32.657 1.422.653

2017-05-11 2017-05-09 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value P - Purchase 21.797 949.458 2,35 2,29 49.869 2.172.265

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.630.471

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.310.352

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 1.870.417

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.630.471

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.310.352

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 1.870.417

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.630.471

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.310.352

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 1.870.417

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.630.471

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.310.352

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 1.870.417

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.630.471

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.310.352

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 1.870.417

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.630.471

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.310.352

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 1.870.417

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.630.471

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.310.352

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 1.870.417

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.630.471

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 2.310.352

2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 1.870.417

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.665.288

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.098.367

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 3.319.001

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.665.288

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.098.367

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 3.319.001

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.665.288

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.098.367

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 3.319.001

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.665.288

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.098.367

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 3.319.001

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.665.288

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.098.367

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 3.319.001

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.665.288

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.098.367

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 3.319.001

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.665.288

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.098.367

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 3.319.001

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.665.288

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 4.098.367

2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 3.319.001

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 2.197.761

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.955.112

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.626.449

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.734.678

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 2.197.761

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.955.112

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.626.449

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.734.678

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 2.197.761

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.955.112

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.626.449

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.734.678

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 2.197.761

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.955.112

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.626.449

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.734.678

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 2.197.761

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.955.112

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.626.449

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.734.678

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 2.197.761

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.955.112

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.626.449

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.734.678

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 2.197.761

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.955.112

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.626.449

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.734.678

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 2.197.761

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.955.112

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.626.449

2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 1.734.678

2017-01-05 2017-01-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 3.234 2.339.083 0,14 1,34 4.333 3.133.669

2017-01-05 2017-01-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 1.145 3.631.103 0,03 1,34 1.534 4.864.589

2016-12-30 2016-12-30 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 1.205 2.335.849 0,05 1,34 1.614 3.129.103

2016-12-30 2016-12-30 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 2.348 3.629.958 0,06 1,34 3.145 4.862.692

2016-12-30 2016-12-28 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 77.076 698.623 12,40 1,34 102.943 933.081

2016-12-30 2016-12-28 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 260.046 2.334.644 12,53 1,34 347.317 3.118.151

2016-12-30 2016-12-28 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 401.726 3.627.610 12,45 1,34 536.545 4.845.036

2016-12-20 2016-12-20 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 2.244 621.547 0,36 1,35 3.040 842.134

2016-12-20 2016-12-20 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 8.111 2.074.598 0,39 1,35 10.990 2.810.873

2016-12-20 2016-12-20 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 11.646 3.225.884 0,36 1,35 15.779 4.370.750

2016-12-20 2016-12-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 21.021 619.303 3,51 1,36 28.555 841.261

2016-12-20 2016-12-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 69.041 2.066.487 3,46 1,36 93.785 2.807.116

2016-12-20 2016-12-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 108.202 3.214.238 3,48 1,36 146.982 4.366.221

2016-12-20 2016-12-16 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 47.812 598.282 8,69 1,28 61.199 765.801

2016-12-20 2016-12-16 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 150.451 1.997.446 8,15 1,28 192.577 2.556.731

2016-12-20 2016-12-16 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 236.393 3.106.036 8,24 1,28 302.583 3.975.726

2016-12-02 2016-12-02 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 2.916 550.470 0,53 1,19 3.470 655.114

2016-12-02 2016-12-02 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 18.586 1.846.995 1,02 1,19 22.119 2.198.109

2016-12-02 2016-12-02 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 30.998 2.869.643 1,09 1,19 36.891 3.415.162

2016-12-02 2016-12-01 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 15.161 547.554 2,85 1,18 17.958 648.578

2016-12-02 2016-12-01 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 52.457 1.828.409 2,95 1,18 62.135 2.165.750

2016-12-02 2016-12-01 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value P - Purchase 81.276 2.838.645 2,95 1,18 96.271 3.362.375

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.823.083

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 6.841.666

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.598.107

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.823.083

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 6.841.666

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.598.107

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.823.083

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 6.841.666

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.598.107

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.823.083

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 6.841.666

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.598.107

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.823.083

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 6.841.666

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.598.107

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.823.083

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 6.841.666

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.598.107

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.823.083

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 6.841.666

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.598.107

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 7.823.083

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 6.841.666

2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 5.598.107

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.850.758

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.381.916

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 2.761.110

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.850.758

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.381.916

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 2.761.110

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.850.758

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.381.916

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 2.761.110

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.850.758

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.381.916

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 2.761.110

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.850.758

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.381.916

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 2.761.110

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.850.758

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.381.916

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 2.761.110

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.850.758

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.381.916

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 2.761.110

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.850.758

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 3.381.916

2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 2.761.110

2016-06-27 2016-06-23 4 ONTY Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock A - Award 6.197 6.197 800,00 4.957.600 4.957.600

2016-06-27 2016-06-23 4 ONTY Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock A - Award 1.029 1.029 800,00 823.200 823.200

2016-06-27 2016-06-23 4 ONTY Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock A - Award 4.519 4.519 800,00 3.615.200 3.615.200

2016-06-27 2016-06-23 4 ONTY Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock A - Award 5.505 5.505 800,00 4.404.000 4.404.000

2016-01-11 2016-01-08 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share P - Purchase 58.613 17.263.200 0,34 1,22 71.338 21.011.041

2016-01-11 2016-01-08 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share P - Purchase 32.571 3.090.744 1,07 1,22 39.642 3.761.745

2016-01-11 2016-01-08 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share P - Purchase 90.049 8.850.836 1,03 1,22 109.599 10.772.352

2016-01-11 2016-01-08 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share P - Purchase 186.314 15.592.160 1,21 1,22 226.763 18.977.218

2016-01-11 2016-01-07 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share P - Purchase 8.091 17.204.587 0,05 1,22 9.848 20.939.703

2016-01-11 2016-01-07 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share P - Purchase 29.655 3.058.173 0,98 1,22 36.093 3.722.102

2016-01-11 2016-01-07 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share P - Purchase 87.747 8.760.787 1,01 1,22 106.797 10.662.754

2016-01-11 2016-01-07 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share P - Purchase 508.287 15.405.846 3,41 1,22 618.636 18.750.455

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 23.547.788

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 21.842.395

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 19.541.857

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 29.064.800

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 23.547.788

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 21.842.395

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 19.541.857

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 29.064.800

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 23.547.788

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 21.842.395

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 19.541.857

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 29.064.800

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 23.547.788

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 21.842.395

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 19.541.857

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 29.064.800

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 23.547.788

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 21.842.395

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 19.541.857

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 29.064.800

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 23.547.788

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 21.842.395

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 19.541.857

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 29.064.800

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 23.547.788

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 21.842.395

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 19.541.857

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 29.064.800

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 23.547.788

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 21.842.395

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 19.541.857

2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 29.064.800

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 58.693.172

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 52.468.653

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 46.824.131

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 60.992.109

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 58.693.172

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 52.468.653

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 46.824.131

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 60.992.109

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 58.693.172

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 52.468.653

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 46.824.131

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 60.992.109

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 58.693.172

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 52.468.653

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 46.824.131

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 60.992.109

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 58.693.172

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 52.468.653

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 46.824.131

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 60.992.109

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 58.693.172

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 52.468.653

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 46.824.131

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 60.992.109

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 58.693.172

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 52.468.653

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 46.824.131

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 60.992.109

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 58.693.172

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 52.468.653

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 46.824.131

2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 60.992.109

2015-11-05 2015-11-05 4 CCXI ChemoCentryx, Inc.
Common Stock J - Other -2.384.577 0 -100,00

2015-11-05 2015-11-04 4 CCXI ChemoCentryx, Inc.
Common Stock S - Sale -287.000 2.384.577 -10,74 7,00 -2.009.057 16.692.516

2015-11-05 2015-11-03 4 CCXI ChemoCentryx, Inc.
Common Stock S - Sale -73.000 2.671.577 -2,66 6,98 -509.343 18.640.394

2015-11-02 2015-11-02 4 CCXI ChemoCentryx, Inc.
Common Stock S - Sale -50.000 2.744.577 -1,79 6,97 -348.515 19.130.525

2015-06-11 2015-06-10 4 CCXI ChemoCentryx, Inc.
Common Stock S - Sale -31.000 2.794.577 -1,10 9,01 -279.229 25.171.873

2015-06-11 2015-06-09 4 CCXI ChemoCentryx, Inc.
Common Stock S - Sale -924.700 2.825.577 -24,66 9,00 -8.322.392 25.430.476

2015-02-09 2015-02-05 4 ONTY Oncothyreon Inc.
Preferred Stock, $0.0001 per share J - Other 1.400 1.400

2015-02-09 2015-02-05 4 ONTY Oncothyreon Inc.
Preferred Stock, $0.0001 per share J - Other 2.600 2.600

2015-02-09 2015-02-05 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value J - Other -1.400.000 1.898.293 -42,45

2015-02-09 2015-02-05 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value J - Other -2.600.000 3.762.683 -40,86

2014-12-17 2014-12-17 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value P - Purchase 55.197 3.298.293 1,70 1,73 95.662 5.716.272

2014-12-17 2014-12-17 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value P - Purchase 98.298 6.362.683 1,57 1,73 170.360 11.027.166

2014-12-17 2014-12-15 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value P - Purchase 79.434 3.243.096 2,51 1,88 149.249 6.093.453

2014-12-17 2014-12-15 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value P - Purchase 145.515 6.264.385 2,38 1,88 273.408 11.770.153

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 15.401.402

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 12.446.194

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 15.401.402

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 12.446.194

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 15.401.402

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 12.446.194

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 15.401.402

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 12.446.194

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 15.401.402

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 12.446.194

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 15.401.402

2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 12.446.194

2014-07-16 2014-07-16 4 ONTY Oncothyreon Inc.
Warrants J - Other -242.814 1.223.484 -16,56 1,59 -386.074 1.945.340

2014-07-16 2014-07-16 4 ONTY Oncothyreon Inc.
Warrants J - Other -407.136 2.288.698 -15,10 1,59 -647.346 3.639.030

2014-07-16 2014-07-16 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value J - Other -258.230 2.412.290 -9,67 3,24 -836.665 7.815.820

2014-07-16 2014-07-16 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value J - Other -296.008 4.512.523 -6,16 3,24 -959.066 14.620.575

2014-07-10 2014-07-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value J - Other -494.092 7.058.997 -6,54 4,56 -2.253.060 32.189.026

2014-07-03 2014-07-01 4 CAPS Capstone Therapeutics Corp.
Common Stock, $0.0005 par value J - Other -616.563 3.993.637 -13,37 0,30 -184.969 1.198.091

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 16.369.219

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 14.974.663

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 20.518.746

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 16.369.219

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 14.974.663

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 20.518.746

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 16.369.219

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 14.974.663

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 20.518.746

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 16.369.219

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 14.974.663

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 20.518.746

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 16.369.219

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 14.974.663

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 20.518.746

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 16.369.219

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 14.974.663

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 20.518.746

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 16.369.219

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 14.974.663

2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 20.518.746

2014-03-26 2014-03-25 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -10.203 130.175 -7,27 69,95 -713.734 9.106.171

2014-03-26 2014-03-25 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -18.019 230.125 -7,26 69,95 -1.260.489 16.098.003

2014-03-26 2014-03-24 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -18.306 140.378 -11,54 70,17 -1.284.483 9.849.945

2014-03-26 2014-03-24 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -31.698 248.144 -11,33 70,17 -2.224.163 17.411.594

2014-03-25 2014-03-21 4 RGDO Regado Biosciences Inc
Preferred Stock, $0.001 per share J - Other 2.632 2.632

2014-03-25 2014-03-21 4 RGDO Regado Biosciences Inc
Preferred Stock, $0.001 per share J - Other 4.577 4.577

2014-03-25 2014-03-21 4 RGDO Regado Biosciences Inc
Common Stock, $0.001 par value J - Other -526.436 1.121.221 -31,95

2014-03-25 2014-03-21 4 RGDO Regado Biosciences Inc
Common Stock, $0.001 par value J - Other -915.345 1.979.670 -31,62

2014-03-03 2014-02-27 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -200.827 2.494.521 -7,45 1,09 -218.901 2.719.028

2014-03-03 2014-02-27 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -33.610 438.127 -7,12 1,09 -36.635 477.558

2014-03-03 2014-02-27 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -59.388 772.480 -7,14 1,09 -64.733 842.003

2014-02-26 2014-02-26 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -33.236 2.695.348 -1,22 1,11 -36.869 2.989.950

2014-02-26 2014-02-26 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -4.416 471.737 -0,93 1,11 -4.899 523.298

2014-02-26 2014-02-26 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -7.745 831.868 -0,92 1,11 -8.592 922.791

2014-02-26 2014-02-25 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -151.535 2.728.584 -5,26 1,12 -169.659 3.054.923

2014-02-26 2014-02-25 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -25.060 476.153 -5,00 1,12 -28.057 533.101

2014-02-26 2014-02-25 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -44.147 839.613 -5,00 1,12 -49.427 940.031

2014-02-26 2014-02-24 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -191.804 2.880.119 -6,24 1,16 -222.838 3.346.122

2014-02-26 2014-02-24 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -29.710 501.213 -5,60 1,16 -34.517 582.309

2014-02-26 2014-02-24 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -52.528 883.760 -5,61 1,16 -61.027 1.026.752

2014-02-20 2014-02-20 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -5.359 79.390 -6,32 73,05 -391.464 5.799.273

2014-02-20 2014-02-20 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -112.369 1.685.344 -6,25 73,05 -8.208.319 123.110.840

2014-02-20 2014-02-20 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -10.557 158.684 -6,24 73,05 -771.167 11.591.533

2014-02-20 2014-02-20 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -18.615 279.842 -6,24 73,05 -1.359.787 20.441.870

2014-02-20 2014-02-19 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -2.771 84.749 -3,17 73,03 -202.375 6.189.499

2014-02-20 2014-02-19 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -57.370 1.797.713 -3,09 73,03 -4.189.920 131.292.913

2014-02-20 2014-02-19 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -5.395 169.241 -3,09 73,03 -394.015 12.360.229

2014-02-20 2014-02-19 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -9.464 298.457 -3,07 73,03 -691.187 21.797.300

2014-02-20 2014-02-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -14.003 87.520 -13,79 74,66 -1.045.409 6.533.902

2014-02-20 2014-02-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -153.751 1.855.083 -7,65 74,66 -11.478.450 138.493.262

2014-02-20 2014-02-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -16.331 174.636 -8,55 74,66 -1.219.209 13.037.643

2014-02-20 2014-02-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value S - Sale -16.915 307.921 -5,21 74,66 -1.262.808 22.988.181

2014-02-19 2014-02-19 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -19.077 3.071.923 -0,62 1,11 -21.216 3.416.286

2014-02-19 2014-02-19 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -10.470 530.923 -1,93 1,11 -11.644 590.439

2014-02-19 2014-02-19 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -14.059 936.288 -1,48 1,11 -15.635 1.041.246

2014-02-19 2014-02-18 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -110.885 541.393 -17,00 1,18 -130.623 637.761

2014-02-19 2014-02-18 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -122.443 950.347 -11,41 1,18 -144.238 1.119.509

2014-02-19 2014-02-14 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -15.622 652.278 -2,34 1,16 -18.139 757.360

2014-02-19 2014-02-14 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share S - Sale -13.410 1.072.790 -1,23 1,16 -15.570 1.245.616

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 5.080.487

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 4.222.129

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 5.080.487

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 4.222.129

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 5.080.487

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 4.222.129

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 5.080.487

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 4.222.129

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 5.080.487

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 4.222.129

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 5.080.487

2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 4.222.129

2013-12-05 2013-12-05 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 41.451 1.251.914 3,42 5,03 208.358 6.292.871

2013-12-05 2013-12-05 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 82.849 2.162.381 3,98 5,03 416.449 10.869.424

2013-12-05 2013-12-03 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 16.175 1.210.463 1,35 4,98 80.590 6.031.011

2013-12-05 2013-12-03 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 49.325 2.079.532 2,43 4,98 245.757 10.361.060

2013-11-29 2013-11-27 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock S - Sale -154.578 2.008.834 -7,15 57,07 -8.822.493 114.653.598

2013-11-29 2013-11-27 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock S - Sale -27.058 101.523 -21,04 57,07 -1.544.327 5.794.395

2013-11-29 2013-11-27 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock S - Sale -50.934 190.967 -21,06 57,07 -2.907.043 10.899.384

2013-11-29 2013-11-27 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock S - Sale -86.435 324.836 -21,02 57,07 -4.933.252 18.539.917

2013-11-29 2013-11-26 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock S - Sale -34.917 128.581 -21,36 57,57 -2.010.172 7.402.408

2013-11-29 2013-11-26 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock S - Sale -54.444 241.901 -18,37 57,57 -3.134.341 13.926.241

2013-11-29 2013-11-26 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock S - Sale -119.139 411.271 -22,46 57,57 -6.858.832 23.676.871

2013-11-20 2013-11-19 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock S - Sale -153.056 646.559 -19,14 2,64 -404.343 1.708.080

2013-11-20 2013-11-19 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock S - Sale -331.566 1.123.848 -22,78 2,64 -875.931 2.968.982

2013-11-06 2013-11-06 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 8.371 1.194.288 0,71 4,69 39.235 5.597.628

2013-11-06 2013-11-06 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 11.985 2.030.207 0,59 4,69 56.174 9.515.580

2013-11-06 2013-11-05 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 74.684 1.185.917 6,72 4,97 370.978 5.890.806

2013-11-06 2013-11-05 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 35.526 2.018.222 1,79 4,97 176.468 10.025.114

2013-11-06 2013-11-04 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 5.500 1.111.233 0,50 4,90 26.944 5.443.819

2013-11-05 2013-11-01 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 79.360 2.670.520 3,06 1,78 141.261 4.753.526

2013-11-05 2013-11-01 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 49.640 4.808.531 1,04 1,78 88.359 8.559.185

2013-11-01 2013-11-01 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 25.154 1.105.733 2,33 4,92 123.775 5.440.980

2013-11-01 2013-11-01 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 45.406 1.982.696 2,34 4,92 223.429 9.756.252

2013-11-01 2013-10-31 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 44.584 1.080.579 4,30 4,97 221.373 5.365.399

2013-11-01 2013-10-31 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 79.998 1.937.290 4,31 4,97 397.214 9.619.226

2013-11-01 2013-10-30 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 50.339 1.035.995 5,11 5,04 253.693 5.221.104

2013-11-01 2013-10-30 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 90.744 1.857.292 5,14 5,04 457.323 9.360.194

2013-10-10 2013-10-09 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 29.564 985.656 3,09 5,26 155.445 5.182.481

2013-10-10 2013-10-09 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 53.271 1.766.548 3,11 5,26 280.094 9.288.333

2013-10-10 2013-10-08 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 401.675 956.092 72,45 5,35 2.148.961 5.115.092

2013-10-10 2013-10-08 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 30.406 554.417 5,80 5,31 161.310 2.941.293

2013-10-10 2013-10-08 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 726.626 1.713.277 73,65 5,35 3.887.449 9.166.032

2013-10-10 2013-10-08 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 47.812 986.651 5,09 5,31 253.652 5.234.381

2013-10-07 2013-10-03 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 38.599 524.011 7,95 5,49 212.071 2.879.021

2013-10-07 2013-10-03 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 70.826 938.839 8,16 5,49 389.132 5.158.169

2013-09-25 2013-09-23 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock S - Sale -147.806 296.345 -33,28 44,50 -6.577.367 13.187.352

2013-09-25 2013-09-23 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock S - Sale -211.217 530.410 -28,48 44,50 -9.399.156 23.603.245

2013-09-13 2013-09-13 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 3.370 485.412 0,70 6,09 20.520 2.955.722

2013-09-13 2013-09-13 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 6.307 868.013 0,73 6,09 38.404 5.285.418

2013-09-13 2013-09-11 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 105.892 482.042 28,15 5,94 629.136 2.863.956

2013-09-13 2013-09-11 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 210.066 861.706 32,24 5,94 1.248.065 5.119.654

2013-08-12 2013-08-08 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 177.940 2.591.160 7,37 1,65 293.512 4.274.118

2013-08-12 2013-08-08 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 80.421 4.758.891 1,72 1,65 132.654 7.849.791

2013-08-02 2013-08-01 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 35.703 2.413.220 1,50 1,78 63.651 4.302.289

2013-08-02 2013-08-01 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 122.641 4.678.470 2,69 1,78 218.644 8.340.776

2013-08-02 2013-07-31 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 179.743 4.555.829 4,11 1,71 307.307 7.789.101

2013-06-11 2013-06-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock P - Purchase 8.102 799.615 1,02 3,47 28.095 2.772.825

2013-06-11 2013-06-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock P - Purchase 24.598 1.455.414 1,72 3,47 85.298 5.046.939

2013-06-07 2013-06-07 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 41.526 2.377.517 1,78 1,83 76.009 4.351.807

2013-06-07 2013-06-07 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 74.726 4.376.086 1,74 1,83 136.778 8.009.988

2013-06-07 2013-06-06 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 27.384 2.335.991 1,19 1,78 48.768 4.160.166

2013-06-07 2013-06-06 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 55.531 4.301.360 1,31 1,78 98.895 7.660.292

2013-06-07 2013-06-05 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 5.000 2.308.607 0,22 1,75 8.750 4.040.062

2013-06-07 2013-06-05 4 ONTY Oncothyreon Inc.
Common Stock P - Purchase 10.300 4.245.829 0,24 1,75 18.025 7.430.201

2013-06-07 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 4.235.529

2013-06-07 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 2.303.607

2013-06-07 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 1.298.842

2013-05-15 3 RIGL RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value 1.430.816

2013-05-15 3 RIGL RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value 791.513

2013-05-15 3 RIGL RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value 6.962.123

2013-05-15 3 RIGL RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value 513.545

2013-01-25 2013-01-23 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock P - Purchase 39.600 2.163.412 1,86 19,78 783.181 42.786.448

2012-12-18 2012-12-14 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock P - Purchase 5.386 2.123.812 0,25 18,63 100.365 39.575.962

2012-12-10 2012-12-06 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock P - Purchase 50.100 2.118.426 2,42 17,94 898.959 38.011.553

2012-11-20 2012-11-16 4/A TRGT TARGACEPT INC
Common Stock P - Purchase 217.000 1.713.907 14,50 4,00 867.935 6.855.114

2012-11-20 2012-11-16 4/A TRGT TARGACEPT INC
Common Stock P - Purchase 378.000 2.977.919 14,54 4,00 1.511.887 11.910.783

2012-11-19 2012-11-16 4 TRGT TARGACEPT INC
Common Stock P - Purchase 26.800 1.523.707 1,79 5,11 136.902 7.783.552

2012-11-19 2012-11-16 4 TRGT TARGACEPT INC
Common Stock P - Purchase 46.700 2.646.619 1,80 5,11 238.558 13.519.724

2012-11-19 2012-11-14 4 TRGT TARGACEPT INC
Common Stock P - Purchase 444.649 1.496.907 42,26 4,00 1.778.596 5.987.628

2012-11-19 2012-11-14 4 TRGT TARGACEPT INC
Common Stock P - Purchase 772.063 2.599.919 42,24 4,00 3.088.252 10.399.676

2012-11-19 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 790.501

2012-11-19 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 456.746

2012-11-19 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 9.894.589

2012-11-19 2012-11-06 4/A CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 40.000 3.750.277 1,08 12,00 479.828 44.987.198

2012-11-19 2012-10-31 4/A LGND LIGAND PHARMACEUTICALS INC
Common Stock P - Purchase 4.076 741.627 0,55 14,99 61.096 11.116.395

2012-11-19 2012-10-26 4/A LGND LIGAND PHARMACEUTICALS INC
Common Stock P - Purchase 12.515 737.551 1,73 15,26 190.926 11.251.931

2012-11-09 2012-11-08 4 TRGT TARGACEPT INC
Common Stock P - Purchase 17.400 1.052.258 1,68 4,01 69.718 4.216.187

2012-11-09 2012-11-08 4 TRGT TARGACEPT INC
Common Stock P - Purchase 31.929 1.827.856 1,78 4,01 127.933 7.323.853

2012-11-09 2012-11-07 4 TRGT TARGACEPT INC
Common Stock P - Purchase 8.800 1.034.858 0,86 4,08 35.915 4.223.462

2012-11-09 2012-11-07 4 TRGT TARGACEPT INC
Common Stock P - Purchase 14.300 1.795.927 0,80 4,08 58.361 7.329.537

2012-11-08 2012-11-06 4 CCXI ChemoCentryx, Inc.
Common Stock P - Purchase 40.000 3.750.277 1,08 12,00 479.828 44.987.198

2012-11-02 2012-10-31 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock P - Purchase 4.076 741.627 0,55 14,99 61.096 11.116.395

2012-11-02 2012-10-26 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock P - Purchase 12.515 737.551 1,73 15,26 190.926 11.251.931

2012-11-02 2012-11-02 4 TRGT TARGACEPT INC
Common Stock P - Purchase 21.500 1.026.058 2,14 4,05 87.150 4.159.126

2012-11-02 2012-11-02 4 TRGT TARGACEPT INC
Common Stock P - Purchase 36.100 1.781.627 2,07 4,05 146.331 7.221.825

2012-11-02 2012-11-01 4 TRGT TARGACEPT INC
CommonStock P - Purchase 23.400 1.004.558 2,38 4,05 94.688 4.064.944

2012-11-02 2012-11-01 4 TRGT TARGACEPT INC
Common Stock P - Purchase 6.700 1.745.527 0,39 4,05 27.112 7.063.275

2012-11-02 2012-10-31 4 TRGT TARGACEPT INC
Common Stock P - Purchase 5.300 981.158 0,54 4,06 21.495 3.979.283

2012-11-02 2012-10-31 4 TRGT TARGACEPT INC
Common Stock P - Purchase 46.700 1.738.827 2,76 4,06 189.401 7.052.161

2012-09-10 3 TRGT TARGACEPT INC
Common Stock, $0.001 par value 1.692.127

2012-09-10 3 TRGT TARGACEPT INC
Common Stock, $0.001 par value 975.858

2012-09-10 3 TRGT TARGACEPT INC
Common Stock, $0.001 par value 349.482

2012-08-31 3 CCXI ChemoCentryx, Inc.
Common Stock, $0.001 par value 651.640

2012-08-31 3 CCXI ChemoCentryx, Inc.
Common Stock, $0.001 par value 376.150

2012-08-31 3 CCXI ChemoCentryx, Inc.
Common Stock, $0.001 par value 3.710.277

P

Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer

S

Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer

A

Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)

C

Konvertering af derivat

D

Salg eller overførsel af værdipapirer tilbage til virksomheden

F

Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet

G

Gave af værdipapirer af eller til insideren

K

Aktieswaps og lignende sikringstransaktioner

M

Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)

V

En transaktion rapporteret frivilligt på formular 4

J

Andet (ledsaget af en fodnote, der beskriver transaktionen)

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2020-05-21	CALA	BVF PARTNERS L P/IL	1.027.016	6,0000	51.351	120,0000	6.162.096	354	39.2	-4.149.176	-67,33
2020-05-21	CALA	BVF PARTNERS L P/IL	1.064.332	6,0000	53.217	120,0000	6.385.992
2020-05-21	CALA	BVF PARTNERS L P/IL	192.250	6,0000	9.612	120,0000	1.153.500

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2017-07-14	CAPS	BVF PARTNERS L P/IL	3.993.637	0,0600	3.994	60,0000	239.618	182	0.0450	-239.438	-99,93
2017-07-14	CAPS	BVF PARTNERS L P/IL	242.236	0,0600	242	60,0000	14.534
2017-07-14	CAPS	BVF PARTNERS L P/IL	105.713	0,0600	106	60,0000	6.343

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2022-06-01	CGEM	BVF PARTNERS L P/IL	405.641	10,9994	405.641	10,9994	4.461.808	48	15.4200	1.793.177	40,19
2022-06-01	CGEM	BVF PARTNERS L P/IL	301.009	10,9994	301.009	10,9994	3.310.918
2022-06-01	CGEM	BVF PARTNERS L P/IL	44.746	10,9994	44.746	10,9994	492.179
2022-05-13	CGEM	BVF PARTNERS L P/IL	53.598	9,1350	53.598	9,1350	489.618
2022-05-13	CGEM	BVF PARTNERS L P/IL	38.558	9,1350	38.558	9,1350	352.227
2022-05-13	CGEM	BVF PARTNERS L P/IL	17.744	9,1350	17.744	9,1350	162.091
2022-05-12	CGEM	BVF PARTNERS L P/IL	542.999	9,0600	542.999	9,0600	4.919.571
2022-05-12	CGEM	BVF PARTNERS L P/IL	457.001	9,0600	457.001	9,0600	4.140.429
2022-04-01	CGEM	BVF PARTNERS L P/IL	266.598	10,7499	266.598	10,7499	2.865.902
2022-04-01	CGEM	BVF PARTNERS L P/IL	9.402	10,7499	9.402	10,7499	101.071

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2019-12-11	CYTK	BVF PARTNERS L P/IL	60.103	9,5150	60.103	9,5150	571.880	217	28.9600	1.168.703	204,36
2019-12-11	CYTK	BVF PARTNERS L P/IL	49.804	9,5150	49.804	9,5150	473.885
2019-12-11	CYTK	BVF PARTNERS L P/IL	8.506	9,5150	8.506	9,5150	80.935
2019-12-10	CYTK	BVF PARTNERS L P/IL	113.529	9,4000	113.529	9,4000	1.067.173
2019-12-10	CYTK	BVF PARTNERS L P/IL	95.100	9,4000	95.100	9,4000	893.940
2019-12-10	CYTK	BVF PARTNERS L P/IL	15.030	9,4000	15.030	9,4000	141.282

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2020-12-09	CYTK	BVF PARTNERS L P/IL	239.274	18,0000	239.274	18,0000	4.306.932	217	18.5400	129.208	3,00
2020-12-09	CYTK	BVF PARTNERS L P/IL	166.194	18,0000	166.194	18,0000	2.991.492
2020-12-09	CYTK	BVF PARTNERS L P/IL	25.486	18,0000	25.486	18,0000	458.748
2020-02-13	CYTK	BVF PARTNERS L P/IL	486.344	15,7868	486.344	15,7868	7.677.815
2020-02-13	CYTK	BVF PARTNERS L P/IL	510.793	15,7868	510.793	15,7868	8.063.787
2020-02-13	CYTK	BVF PARTNERS L P/IL	74.893	15,7868	74.893	15,7868	1.182.321

Handelsdato	Ticker	Insider	Rapporteret Aktier	Justeret Aktier	dage til Maks	Pris kl Maks
2024-05-09	ELDN	BVF PARTNERS L P/IL	1.031.385	1.031.385	176	5.3000
2024-05-09	ELDN	BVF PARTNERS L P/IL	821.121	821.121
2024-05-09	ELDN	BVF PARTNERS L P/IL	75.431	75.431
2023-05-05	ELDN	BVF PARTNERS L P/IL	1.055.445	1.055.445
2023-05-05	ELDN	BVF PARTNERS L P/IL	837.146	837.146
2023-05-05	ELDN	BVF PARTNERS L P/IL	86.341	86.341

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2025-08-05	EPIX	BVF PARTNERS L P/IL	79	1,8779	79	1,8779	148	30	0.2316	-130	-87,64
2025-08-05	EPIX	BVF PARTNERS L P/IL	66	1,8779	66	1,8779	124
2025-08-05	EPIX	BVF PARTNERS L P/IL	11	1,8779	11	1,8779	21

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2020-06-30	IDYA	BVF PARTNERS L P/IL	1.521	13,3164	1.521	13,3164	20.254	279	24.83	17.512	86,46
2020-06-30	IDYA	BVF PARTNERS L P/IL	929	13,3164	929	13,3164	12.371
2020-06-30	IDYA	BVF PARTNERS L P/IL	81	13,3164	81	13,3164	1.079
2020-06-22	IDYA	BVF PARTNERS L P/IL	10.524	13,9347	10.524	13,9347	146.649
2020-06-22	IDYA	BVF PARTNERS L P/IL	7.854	13,9347	7.854	13,9347	109.443
2020-06-22	IDYA	BVF PARTNERS L P/IL	1.354	13,9347	1.354	13,9347	18.868
2020-06-19	IDYA	BVF PARTNERS L P/IL	52.443	14,3895	52.443	14,3895	754.629
2020-06-19	IDYA	BVF PARTNERS L P/IL	39.052	14,3895	39.052	14,3895	561.939
2020-06-19	IDYA	BVF PARTNERS L P/IL	6.769	14,3895	6.769	14,3895	97.403

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2021-02-02	IDYA	BVF PARTNERS L P/IL	25.234	18,0000	25.234	18,0000	454.212	359	15.2100	-70.403	-15,50
2021-02-02	IDYA	BVF PARTNERS L P/IL	16.850	18,0000	16.850	18,0000	303.300
2021-02-02	IDYA	BVF PARTNERS L P/IL	4.325	18,0000	4.325	18,0000	77.850

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2018-12-13	INFI	BVF PARTNERS L P/IL	54.461	1,1995	54.461	1,1995	65.326	91	1.9100	38.696	59,24
2018-12-13	INFI	BVF PARTNERS L P/IL	120.539	1,1995	120.539	1,1995	144.587
2018-11-28	INFI	BVF PARTNERS L P/IL	100.000	1,3000	100.000	1,3000	130.000
2018-11-21	INFI	BVF PARTNERS L P/IL	4.119	1,3500	4.119	1,3500	5.561
2018-11-21	INFI	BVF PARTNERS L P/IL	581	1,3500	581	1,3500	784
2018-11-19	INFI	BVF PARTNERS L P/IL	733.151	1,3698	733.151	1,3698	1.004.270
2018-11-19	INFI	BVF PARTNERS L P/IL	556.709	1,3698	556.709	1,3698	762.580
2018-11-19	INFI	BVF PARTNERS L P/IL	81.648	1,3698	81.648	1,3698	111.841
2018-11-19	INFI	BVF PARTNERS L P/IL	50.044	1,3500	50.044	1,3500	67.559
2018-11-19	INFI	BVF PARTNERS L P/IL	38.001	1,3500	38.001	1,3500	51.301
2018-11-19	INFI	BVF PARTNERS L P/IL	5.573	1,3500	5.573	1,3500	7.524
2018-11-15	INFI	BVF PARTNERS L P/IL	52.400	1,3500	52.400	1,3500	70.740
2018-11-15	INFI	BVF PARTNERS L P/IL	39.074	1,3500	39.074	1,3500	52.750
2018-11-14	INFI	BVF PARTNERS L P/IL	117.290	1,3400	117.290	1,3400	157.169
2018-11-14	INFI	BVF PARTNERS L P/IL	92.960	1,3400	92.960	1,3400	124.566
2018-11-13	INFI	BVF PARTNERS L P/IL	41.454	1,3500	41.454	1,3500	55.963
2018-11-13	INFI	BVF PARTNERS L P/IL	562.754	1,3500	562.754	1,3500	759.718
2018-06-21	INFI	BVF PARTNERS L P/IL	230.555	1,6500	230.555	1,6500	380.416
2018-06-21	INFI	BVF PARTNERS L P/IL	158.151	1,6500	158.151	1,6500	260.949
2018-06-21	INFI	BVF PARTNERS L P/IL	36.825	1,6500	36.825	1,6500	60.761
2018-06-19	INFI	BVF PARTNERS L P/IL	1.916.760	1,6500	1.916.760	1,6500	3.162.654
2018-06-19	INFI	BVF PARTNERS L P/IL	1.419.907	1,6500	1.419.907	1,6500	2.342.847
2018-06-19	INFI	BVF PARTNERS L P/IL	179.893	1,6500	179.893	1,6500	296.823
2018-04-10	INFI	BVF PARTNERS L P/IL	546.865	2,0000	546.865	2,0000	1.093.730
2018-04-10	INFI	BVF PARTNERS L P/IL	365.682	2,0000	365.682	2,0000	731.364
2018-04-10	INFI	BVF PARTNERS L P/IL	97.453	2,0000	97.453	2,0000	194.906
2018-04-09	INFI	BVF PARTNERS L P/IL	228.691	1,9000	228.691	1,9000	434.513
2018-04-09	INFI	BVF PARTNERS L P/IL	208.872	1,9000	208.872	1,9000	396.857
2018-04-09	INFI	BVF PARTNERS L P/IL	62.437	1,9000	62.437	1,9000	118.630
2017-10-04	INFI	BVF PARTNERS L P/IL	355.081	1,2840	355.081	1,2840	455.924
2017-10-04	INFI	BVF PARTNERS L P/IL	235.326	1,2840	235.326	1,2840	302.159
2017-10-04	INFI	BVF PARTNERS L P/IL	63.042	1,2840	63.042	1,2840	80.946
2017-10-03	INFI	BVF PARTNERS L P/IL	523.601	1,2350	523.601	1,2350	646.647
2017-10-03	INFI	BVF PARTNERS L P/IL	394.078	1,2350	394.078	1,2350	486.686
2017-10-03	INFI	BVF PARTNERS L P/IL	28.918	1,2350	28.918	1,2350	35.714
2017-01-03	INFI	BVF PARTNERS L P/IL	1.145	1,3397	1.145	1,3397	1.534
2017-01-03	INFI	BVF PARTNERS L P/IL	3.234	1,3397	3.234	1,3397	4.333
2016-12-30	INFI	BVF PARTNERS L P/IL	2.348	1,3396	2.348	1,3396	3.145
2016-12-30	INFI	BVF PARTNERS L P/IL	1.205	1,3396	1.205	1,3396	1.614
2016-12-28	INFI	BVF PARTNERS L P/IL	401.726	1,3356	401.726	1,3356	536.545
2016-12-28	INFI	BVF PARTNERS L P/IL	260.046	1,3356	260.046	1,3356	347.317
2016-12-28	INFI	BVF PARTNERS L P/IL	77.076	1,3356	77.076	1,3356	102.943
2016-12-20	INFI	BVF PARTNERS L P/IL	11.646	1,3549	11.646	1,3549	15.779
2016-12-20	INFI	BVF PARTNERS L P/IL	8.111	1,3549	8.111	1,3549	10.990
2016-12-20	INFI	BVF PARTNERS L P/IL	2.244	1,3549	2.244	1,3549	3.040
2016-12-19	INFI	BVF PARTNERS L P/IL	108.202	1,3584	108.202	1,3584	146.982
2016-12-19	INFI	BVF PARTNERS L P/IL	69.041	1,3584	69.041	1,3584	93.785
2016-12-19	INFI	BVF PARTNERS L P/IL	21.021	1,3584	21.021	1,3584	28.555
2016-12-16	INFI	BVF PARTNERS L P/IL	236.393	1,2800	236.393	1,2800	302.583
2016-12-16	INFI	BVF PARTNERS L P/IL	150.451	1,2800	150.451	1,2800	192.577
2016-12-16	INFI	BVF PARTNERS L P/IL	47.812	1,2800	47.812	1,2800	61.199
2016-12-02	INFI	BVF PARTNERS L P/IL	30.998	1,1901	30.998	1,1901	36.891
2016-12-02	INFI	BVF PARTNERS L P/IL	18.586	1,1901	18.586	1,1901	22.119
2016-12-02	INFI	BVF PARTNERS L P/IL	2.916	1,1901	2.916	1,1901	3.470
2016-12-01	INFI	BVF PARTNERS L P/IL	81.276	1,1845	81.276	1,1845	96.271
2016-12-01	INFI	BVF PARTNERS L P/IL	52.457	1,1845	52.457	1,1845	62.135
2016-12-01	INFI	BVF PARTNERS L P/IL	15.161	1,1845	15.161	1,1845	17.958

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2021-02-11	INFI	BVF PARTNERS L P/IL	1.215.491	5,3686	1.215.491	5,3686	6.525.485	350	1.1100	-5.176.289	-79,32
2021-02-11	INFI	BVF PARTNERS L P/IL	892.467	5,3686	892.467	5,3686	4.791.298
2021-02-11	INFI	BVF PARTNERS L P/IL	152.127	5,3686	152.127	5,3686	816.709
2021-01-22	INFI	BVF PARTNERS L P/IL	2.821.663	4,1388	2.821.663	4,1388	11.678.299
2021-01-22	INFI	BVF PARTNERS L P/IL	2.458.838	4,1388	2.458.838	4,1388	10.176.639
2021-01-22	INFI	BVF PARTNERS L P/IL	568.019	4,1388	568.019	4,1388	2.350.917

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2025-06-30	KYMR	BVF PARTNERS L P/IL	142.604	44,0000	142.604	44,0000	6.274.576	23	46.4300	346.528	5,52
2025-06-30	KYMR	BVF PARTNERS L P/IL	115.783	44,0000	115.783	44,0000	5.094.452
2025-06-30	KYMR	BVF PARTNERS L P/IL	58.780	44,0000	58.780	44,0000	2.586.320
2023-11-03	KYMR	BVF PARTNERS L P/IL	103.885	14,0689	103.885	14,0689	1.461.548
2023-11-03	KYMR	BVF PARTNERS L P/IL	83.708	14,0689	83.708	14,0689	1.177.679
2023-11-03	KYMR	BVF PARTNERS L P/IL	10.106	14,0689	10.106	14,0689	142.180
2023-11-02	KYMR	BVF PARTNERS L P/IL	57.618	11,6444	57.618	11,6444	670.927
2023-11-02	KYMR	BVF PARTNERS L P/IL	132.016	11,6444	132.016	11,6444	1.537.247
2023-11-02	KYMR	BVF PARTNERS L P/IL	26.772	11,6444	26.772	11,6444	311.744
2023-01-12	KYMR	BVF PARTNERS L P/IL	2.985	31,2426	2.985	31,2426	93.259
2023-01-12	KYMR	BVF PARTNERS L P/IL	15.912	31,2426	15.912	31,2426	497.132
2023-01-11	KYMR	BVF PARTNERS L P/IL	10.961	29,8869	10.961	29,8869	327.590
2023-01-11	KYMR	BVF PARTNERS L P/IL	11.149	29,8869	11.149	29,8869	333.209
2022-08-22	KYMR	BVF PARTNERS L P/IL	285.046	26,0000	285.046	26,0000	7.411.196
2022-08-22	KYMR	BVF PARTNERS L P/IL	233.362	26,0000	233.362	26,0000	6.067.412
2022-08-22	KYMR	BVF PARTNERS L P/IL	27.117	26,0000	27.117	26,0000	705.042
2022-05-27	KYMR	BVF PARTNERS L P/IL	35.793	14,7828	35.793	14,7828	529.121
2022-05-27	KYMR	BVF PARTNERS L P/IL	26.353	14,7828	26.353	14,7828	389.571
2022-05-27	KYMR	BVF PARTNERS L P/IL	3.223	14,7828	3.223	14,7828	47.645
2022-05-26	KYMR	BVF PARTNERS L P/IL	123.043	14,2106	123.043	14,2106	1.748.515
2022-05-26	KYMR	BVF PARTNERS L P/IL	90.372	14,2106	90.372	14,2106	1.284.240
2022-05-26	KYMR	BVF PARTNERS L P/IL	10.642	14,2106	10.642	14,2106	151.229
2022-05-20	KYMR	BVF PARTNERS L P/IL	5.883	13,9994	5.883	13,9994	82.358
2022-05-20	KYMR	BVF PARTNERS L P/IL	4.180	13,9994	4.180	13,9994	58.517
2022-05-20	KYMR	BVF PARTNERS L P/IL	37	13,9994	37	13,9994	518
2022-05-06	KYMR	BVF PARTNERS L P/IL	55.210	19,2550	55.210	19,2550	1.063.069
2022-05-06	KYMR	BVF PARTNERS L P/IL	40.659	19,2550	40.659	19,2550	782.889
2022-05-06	KYMR	BVF PARTNERS L P/IL	4.131	19,2550	4.131	19,2550	79.542
2022-05-05	KYMR	BVF PARTNERS L P/IL	75.495	19,5991	75.495	19,5991	1.479.634
2022-05-05	KYMR	BVF PARTNERS L P/IL	70.439	19,5991	70.439	19,5991	1.380.541
2022-05-05	KYMR	BVF PARTNERS L P/IL	4.066	19,5991	4.066	19,5991	79.690
2022-01-31	KYMR	BVF PARTNERS L P/IL	20.085	40,7000	20.085	40,7000	817.460
2022-01-31	KYMR	BVF PARTNERS L P/IL	14.323	40,7000	14.323	40,7000	582.946
2022-01-27	KYMR	BVF PARTNERS L P/IL	58.042	38,3319	58.042	38,3319	2.224.860
2022-01-27	KYMR	BVF PARTNERS L P/IL	37.859	38,3319	37.859	38,3319	1.451.207
2022-01-24	KYMR	BVF PARTNERS L P/IL	158.041	37,7635	158.041	37,7635	5.968.181
2022-01-24	KYMR	BVF PARTNERS L P/IL	114.726	37,7635	114.726	37,7635	4.332.455
2021-07-01	KYMR	BVF PARTNERS L P/IL	304.997	47,0000	304.997	47,0000	14.334.859
2021-07-01	KYMR	BVF PARTNERS L P/IL	211.711	47,0000	211.711	47,0000	9.950.417
2021-07-01	KYMR	BVF PARTNERS L P/IL	27.458	47,0000	27.458	47,0000	1.290.526

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2024-10-04	MLTX	BVF PARTNERS L P/IL	1.030.589	50,0016	1.030.589	50,0016	51.531.099	186	32.8350	-17.691.708	-34,33
2024-10-04	MLTX	BVF PARTNERS L P/IL	836.862	50,0016	836.862	50,0016	41.844.439
2024-10-04	MLTX	BVF PARTNERS L P/IL	132.549	50,0016	132.549	50,0016	6.627.662

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2021-03-30	MRUS	BVF PARTNERS L P/IL	165.000	19,7500	165.000	19,7500	3.258.750	275	32.29	2.069.100	63,49
2021-03-30	MRUS	BVF PARTNERS L P/IL	108.106	19,7500	108.106	19,7500	2.135.094
2021-03-30	MRUS	BVF PARTNERS L P/IL	26.894	19,7500	26.894	19,7500	531.156
2021-03-22	MRUS	BVF PARTNERS L P/IL	71.756	22,7500	71.756	22,7500	1.632.449
2021-03-22	MRUS	BVF PARTNERS L P/IL	7.744	22,7500	7.744	22,7500	176.176
2021-03-16	MRUS	BVF PARTNERS L P/IL	53.061	22,9996	53.061	22,9996	1.220.382
2021-03-16	MRUS	BVF PARTNERS L P/IL	195.768	22,9996	195.768	22,9996	4.502.586
2021-03-16	MRUS	BVF PARTNERS L P/IL	1.171	22,9996	1.171	22,9996	26.933
2021-01-21	MRUS	BVF PARTNERS L P/IL	457.814	24,7500	457.814	24,7500	11.330.896
2021-01-21	MRUS	BVF PARTNERS L P/IL	343.444	24,7500	343.444	24,7500	8.500.239
2021-01-21	MRUS	BVF PARTNERS L P/IL	43.422	24,7500	43.422	24,7500	1.074.694
2020-12-18	MRUS	BVF PARTNERS L P/IL	114.968	16,0500	114.968	16,0500	1.845.236
2020-12-18	MRUS	BVF PARTNERS L P/IL	45.032	16,0500	45.032	16,0500	722.764
2020-09-15	MRUS	BVF PARTNERS L P/IL	77.751	11,7500	77.751	11,7500	913.574
2020-09-15	MRUS	BVF PARTNERS L P/IL	58.745	11,7500	58.745	11,7500	690.254
2020-09-15	MRUS	BVF PARTNERS L P/IL	10.258	11,7500	10.258	11,7500	120.532
2020-09-10	MRUS	BVF PARTNERS L P/IL	100.461	11,0982	100.461	11,0982	1.114.936
2020-09-10	MRUS	BVF PARTNERS L P/IL	76.374	11,0982	76.374	11,0982	847.614
2020-09-10	MRUS	BVF PARTNERS L P/IL	12.816	11,0982	12.816	11,0982	142.235
2020-09-03	MRUS	BVF PARTNERS L P/IL	104.827	11,1700	104.827	11,1700	1.170.918
2020-09-03	MRUS	BVF PARTNERS L P/IL	82.740	11,1700	82.740	11,1700	924.206
2020-09-03	MRUS	BVF PARTNERS L P/IL	14.339	11,1700	14.339	11,1700	160.167
2020-06-08	MRUS	BVF PARTNERS L P/IL	46.966	15,2000	46.966	15,2000	713.883
2020-06-08	MRUS	BVF PARTNERS L P/IL	33.321	15,2000	33.321	15,2000	506.479
2020-06-08	MRUS	BVF PARTNERS L P/IL	6.967	15,2000	6.967	15,2000	105.898
2020-06-01	MRUS	BVF PARTNERS L P/IL	806.443	14,0000	806.443	14,0000	11.290.202
2020-06-01	MRUS	BVF PARTNERS L P/IL	561.966	14,0000	561.966	14,0000	7.867.524
2020-06-01	MRUS	BVF PARTNERS L P/IL	94.101	14,0000	94.101	14,0000	1.317.414
2020-01-16	MRUS	BVF PARTNERS L P/IL	146.442	16,1500	146.442	16,1500	2.365.038
2020-01-16	MRUS	BVF PARTNERS L P/IL	112.561	16,1500	112.561	16,1500	1.817.860
2020-01-16	MRUS	BVF PARTNERS L P/IL	19.727	16,1500	19.727	16,1500	318.591
2020-01-13	MRUS	BVF PARTNERS L P/IL	53.448	14,9784	53.448	14,9784	800.566
2020-01-13	MRUS	BVF PARTNERS L P/IL	25.108	14,9784	25.108	14,9784	376.078
2020-01-13	MRUS	BVF PARTNERS L P/IL	5.406	14,9784	5.406	14,9784	80.973

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2021-10-08	MRUS	BVF PARTNERS L P/IL	80.011	27,7865	80.011	27,7865	2.223.226	230	13.9800	-1.104.671	-49,69
2021-10-08	MRUS	BVF PARTNERS L P/IL	58.327	27,7865	58.327	27,7865	1.620.703
2021-10-08	MRUS	BVF PARTNERS L P/IL	8.929	27,7865	8.929	27,7865	248.106
2021-10-07	MRUS	BVF PARTNERS L P/IL	530.999	27,5311	530.999	27,5311	14.618.987
2021-10-07	MRUS	BVF PARTNERS L P/IL	384.914	27,5311	384.914	27,5311	10.597.106
2021-10-07	MRUS	BVF PARTNERS L P/IL	69.534	27,5311	69.534	27,5311	1.914.348
2021-07-02	MRUS	BVF PARTNERS L P/IL	1.106.478	20,7500	1.106.478	20,7500	22.959.418
2021-07-02	MRUS	BVF PARTNERS L P/IL	928.739	20,7500	928.739	20,7500	19.271.334
2021-07-02	MRUS	BVF PARTNERS L P/IL	150.805	20,7500	150.805	20,7500	3.129.204

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2023-09-12	OLMA	BVF PARTNERS L P/IL	775.278	9,8400	775.278	9,8400	7.628.736	57	17.1400	5.659.530	74,19
2023-09-12	OLMA	BVF PARTNERS L P/IL	677.853	9,8400	677.853	9,8400	6.670.074
2023-09-12	OLMA	BVF PARTNERS L P/IL	52.801	9,8400	52.801	9,8400	519.562
2022-06-10	OLMA	BVF PARTNERS L P/IL	158.583	4,0345	158.583	4,0345	639.803
2022-06-10	OLMA	BVF PARTNERS L P/IL	41.417	4,0345	41.417	4,0345	167.097
2021-11-30	OLMA	BVF PARTNERS L P/IL	362.430	9,3903	362.430	9,3903	3.403.326
2021-11-30	OLMA	BVF PARTNERS L P/IL	341.977	9,3903	341.977	9,3903	3.211.267
2021-11-30	OLMA	BVF PARTNERS L P/IL	35.268	9,3903	35.268	9,3903	331.177
2020-11-19	OLMA	BVF PARTNERS L P/IL	613.918	19,0000	613.918	19,0000	11.664.442
2020-11-19	OLMA	BVF PARTNERS L P/IL	446.425	19,0000	446.425	19,0000	8.482.075
2020-11-19	OLMA	BVF PARTNERS L P/IL	74.991	19,0000	74.991	19,0000	1.424.829

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2013-06-07	RIGL	BVF PARTNERS L P/IL	24.598	3,4677	2.460	34,6770	85.298	276	47.5	31.504	36,93
2013-06-07	RIGL	BVF PARTNERS L P/IL	8.102	3,4677	810	34,6770	28.095

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2013-11-19	RIGL	BVF PARTNERS L P/IL	331.566	2,6418	33.157	26,4180	875.931	286	2.6	-789.725	-90,16
2013-11-19	RIGL	BVF PARTNERS L P/IL	153.056	2,6418	15.306	26,4180	404.343

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2023-11-16	RPTX	BVF PARTNERS L P/IL	153.693	5,3837	153.693	5,3837	827.437	88	8.4100	465.121	56,21
2023-11-16	RPTX	BVF PARTNERS L P/IL	125.909	5,3837	125.909	5,3837	677.856
2023-11-16	RPTX	BVF PARTNERS L P/IL	16.143	5,3837	16.143	5,3837	86.909
2023-11-15	RPTX	BVF PARTNERS L P/IL	493.337	4,9999	493.337	4,9999	2.466.636
2023-11-15	RPTX	BVF PARTNERS L P/IL	390.507	4,9999	390.507	4,9999	1.952.496
2023-11-15	RPTX	BVF PARTNERS L P/IL	47.712	4,9999	47.712	4,9999	238.555
2023-11-02	RPTX	BVF PARTNERS L P/IL	218.979	3,6000	218.979	3,6000	788.324
2023-11-02	RPTX	BVF PARTNERS L P/IL	492.251	3,6000	492.251	3,6000	1.772.104
2023-11-02	RPTX	BVF PARTNERS L P/IL	72.479	3,6000	72.479	3,6000	260.924
2022-06-13	RPTX	BVF PARTNERS L P/IL	74.666	12,7300	74.666	12,7300	950.498
2022-06-13	RPTX	BVF PARTNERS L P/IL	68.327	12,7300	68.327	12,7300	869.803
2022-06-13	RPTX	BVF PARTNERS L P/IL	6.168	12,7300	6.168	12,7300	78.519
2022-06-06	RPTX	BVF PARTNERS L P/IL	3.809	13,2118	3.809	13,2118	50.324
2022-06-06	RPTX	BVF PARTNERS L P/IL	3.040	13,2118	3.040	13,2118	40.164
2022-06-06	RPTX	BVF PARTNERS L P/IL	20	13,2118	20	13,2118	264
2022-06-03	RPTX	BVF PARTNERS L P/IL	353.344	12,2860	353.344	12,2860	4.341.184
2022-06-03	RPTX	BVF PARTNERS L P/IL	258.797	12,2860	258.797	12,2860	3.179.580
2022-06-03	RPTX	BVF PARTNERS L P/IL	31.903	12,2860	31.903	12,2860	391.960
2022-06-02	RPTX	BVF PARTNERS L P/IL	660.654	11,6824	660.654	11,6824	7.718.024
2022-06-02	RPTX	BVF PARTNERS L P/IL	464.235	11,6824	464.235	11,6824	5.423.379
2022-06-02	RPTX	BVF PARTNERS L P/IL	61.156	11,6824	61.156	11,6824	714.449
2022-05-18	RPTX	BVF PARTNERS L P/IL	224.388	8,5000	224.388	8,5000	1.907.298
2022-05-18	RPTX	BVF PARTNERS L P/IL	189.882	8,5000	189.882	8,5000	1.613.997
2022-05-18	RPTX	BVF PARTNERS L P/IL	5.730	8,5000	5.730	8,5000	48.705
2022-01-19	RPTX	BVF PARTNERS L P/IL	577.798	14,1000	577.798	14,1000	8.146.952
2022-01-19	RPTX	BVF PARTNERS L P/IL	412.264	14,1000	412.264	14,1000	5.812.922
2022-01-19	RPTX	BVF PARTNERS L P/IL	7.899	14,1000	7.899	14,1000	111.376

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2017-08-15	XENE	BVF PARTNERS L P/IL	11.429	2,4122	11.429	2,4122	27.569	359	12.1	110.722	401,62
2017-08-15	XENE	BVF PARTNERS L P/IL	7.429	2,4122	7.429	2,4122	17.920
2017-08-14	XENE	BVF PARTNERS L P/IL	28.007	2,7036	28.007	2,7036	75.720
2017-08-14	XENE	BVF PARTNERS L P/IL	13.337	2,7036	13.337	2,7036	36.058
2017-06-27	XENE	BVF PARTNERS L P/IL	46.795	4,0000	46.795	4,0000	187.180
2017-06-27	XENE	BVF PARTNERS L P/IL	30.170	4,0000	30.170	4,0000	120.680
2017-06-27	XENE	BVF PARTNERS L P/IL	8.496	4,0000	8.496	4,0000	33.984
2017-06-27	XENE	BVF PARTNERS L P/IL	46.795	3,0361	46.795	3,0361	142.074
2017-06-27	XENE	BVF PARTNERS L P/IL	30.170	3,0361	30.170	3,0361	91.599
2017-06-27	XENE	BVF PARTNERS L P/IL	8.496	3,0361	8.496	3,0361	25.795
2017-06-19	XENE	BVF PARTNERS L P/IL	1.967	3,8500	1.967	3,8500	7.573
2017-06-19	XENE	BVF PARTNERS L P/IL	1.271	3,8500	1.271	3,8500	4.893
2017-06-19	XENE	BVF PARTNERS L P/IL	357	3,8500	357	3,8500	1.374
2017-06-16	XENE	BVF PARTNERS L P/IL	6.097	3,8500	6.097	3,8500	23.473
2017-06-16	XENE	BVF PARTNERS L P/IL	3.873	3,8500	3.873	3,8500	14.911
2017-06-16	XENE	BVF PARTNERS L P/IL	1.064	3,8500	1.064	3,8500	4.096
2017-06-15	XENE	BVF PARTNERS L P/IL	6.774	3,8370	6.774	3,8370	25.992
2017-06-15	XENE	BVF PARTNERS L P/IL	3.845	3,8370	3.845	3,8370	14.753
2017-06-15	XENE	BVF PARTNERS L P/IL	1.160	3,8370	1.160	3,8370	4.451
2017-06-07	XENE	BVF PARTNERS L P/IL	113.446	3,8512	113.446	3,8512	436.903
2017-06-07	XENE	BVF PARTNERS L P/IL	73.749	3,8512	73.749	3,8512	284.022
2017-06-07	XENE	BVF PARTNERS L P/IL	20.594	3,8512	20.594	3,8512	79.312
2017-06-06	XENE	BVF PARTNERS L P/IL	96.736	3,7500	96.736	3,7500	362.760
2017-06-06	XENE	BVF PARTNERS L P/IL	53.260	3,7500	53.260	3,7500	199.725
2017-06-06	XENE	BVF PARTNERS L P/IL	913	3,7500	913	3,7500	3.424

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2023-01-06	XOMA	BVF PARTNERS L P/IL	1.676	21,9817	1.676	21,9817	36.841	14	23.1200	1.908	5,18
2023-01-06	XOMA	BVF PARTNERS L P/IL	1.573	21,9817	1.573	21,9817	34.577
2023-01-05	XOMA	BVF PARTNERS L P/IL	3.330	18,3852	3.330	18,3852	61.223
2023-01-05	XOMA	BVF PARTNERS L P/IL	15.670	18,3852	15.670	18,3852	288.096
2022-09-27	XOMA	BVF PARTNERS L P/IL	1.004	16,8902	1.004	16,8902	16.958
2022-09-27	XOMA	BVF PARTNERS L P/IL	678	16,8902	678	16,8902	11.452
2022-09-26	XOMA	BVF PARTNERS L P/IL	3.339	16,8317	3.339	16,8317	56.201
2022-09-26	XOMA	BVF PARTNERS L P/IL	3.021	16,8317	3.021	16,8317	50.849
2022-09-23	XOMA	BVF PARTNERS L P/IL	6.715	16,4970	6.715	16,4970	110.777
2022-09-23	XOMA	BVF PARTNERS L P/IL	9.885	16,4970	9.885	16,4970	163.073
2022-09-16	XOMA	BVF PARTNERS L P/IL	10.897	17,8873	10.897	17,8873	194.918
2022-09-16	XOMA	BVF PARTNERS L P/IL	13.396	17,8873	13.396	17,8873	239.618
2022-09-15	XOMA	BVF PARTNERS L P/IL	5.575	17,9620	5.575	17,9620	100.138
2022-09-14	XOMA	BVF PARTNERS L P/IL	26.441	17,2476	26.441	17,2476	456.044
2020-09-23	XOMA	BVF PARTNERS L P/IL	9.888	18,1998	9.888	18,1998	179.960
2020-09-23	XOMA	BVF PARTNERS L P/IL	7.201	18,1998	7.201	18,1998	131.057
2020-09-22	XOMA	BVF PARTNERS L P/IL	6.960	18,4457	6.960	18,4457	128.382
2020-09-22	XOMA	BVF PARTNERS L P/IL	4.991	18,4457	4.991	18,4457	92.062
2020-09-21	XOMA	BVF PARTNERS L P/IL	12.259	18,3851	12.259	18,3851	225.383
2020-09-21	XOMA	BVF PARTNERS L P/IL	10.069	18,3851	10.069	18,3851	185.120
2020-09-04	XOMA	BVF PARTNERS L P/IL	3.907	18,7706	3.907	18,7706	73.337
2020-09-04	XOMA	BVF PARTNERS L P/IL	3.830	18,7706	3.830	18,7706	71.891
2020-09-01	XOMA	BVF PARTNERS L P/IL	9.900	18,8661	9.900	18,8661	186.774
2020-09-01	XOMA	BVF PARTNERS L P/IL	7.672	18,8661	7.672	18,8661	144.741
2020-08-31	XOMA	BVF PARTNERS L P/IL	9.143	18,4806	9.143	18,4806	168.968
2020-08-31	XOMA	BVF PARTNERS L P/IL	6.862	18,4806	6.862	18,4806	126.814
2020-08-28	XOMA	BVF PARTNERS L P/IL	1.122	19,1719	1.122	19,1719	21.511
2020-08-28	XOMA	BVF PARTNERS L P/IL	922	19,1719	922	19,1719	17.676
2020-08-25	XOMA	BVF PARTNERS L P/IL	3.443	19,7450	3.443	19,7450	67.982
2020-08-25	XOMA	BVF PARTNERS L P/IL	2.244	19,7450	2.244	19,7450	44.308
2020-08-24	XOMA	BVF PARTNERS L P/IL	6.504	19,3093	6.504	19,3093	125.588
2020-08-24	XOMA	BVF PARTNERS L P/IL	5.179	19,3093	5.179	19,3093	100.003
2020-08-21	XOMA	BVF PARTNERS L P/IL	9.198	19,3216	9.198	19,3216	177.720
2020-08-21	XOMA	BVF PARTNERS L P/IL	1.607	19,3216	1.607	19,3216	31.050
2020-08-20	XOMA	BVF PARTNERS L P/IL	1.772	19,1200	1.772	19,1200	33.881
2020-08-19	XOMA	BVF PARTNERS L P/IL	3.496	19,7016	3.496	19,7016	68.877
2020-08-18	XOMA	BVF PARTNERS L P/IL	895	19,2694	895	19,2694	17.246
2020-08-14	XOMA	BVF PARTNERS L P/IL	21.922	18,6940	21.922	18,6940	409.810
2020-08-13	XOMA	BVF PARTNERS L P/IL	1.050	17,8032	1.050	17,8032	18.693
2020-08-12	XOMA	BVF PARTNERS L P/IL	4.050	17,3415	4.050	17,3415	70.233
2020-03-25	XOMA	BVF PARTNERS L P/IL	8.264	17,1986	8.264	17,1986	142.129
2020-03-18	XOMA	BVF PARTNERS L P/IL	4.439	14,5246	4.439	14,5246	64.475
2020-03-17	XOMA	BVF PARTNERS L P/IL	8.113	15,7337	8.113	15,7337	127.648
2020-03-16	XOMA	BVF PARTNERS L P/IL	10.164	15,7336	10.164	15,7336	159.916
2020-03-13	XOMA	BVF PARTNERS L P/IL	100.000	18,3409	100.000	18,3409	1.834.090
2019-12-19	XOMA	BVF PARTNERS L P/IL	207.234	22,0000	207.234	22,0000	4.559.148
2019-12-19	XOMA	BVF PARTNERS L P/IL	165.961	22,0000	165.961	22,0000	3.651.142
2019-05-14	XOMA	BVF PARTNERS L P/IL	13.816	14,7412	13.816	14,7412	203.664
2019-05-13	XOMA	BVF PARTNERS L P/IL	3.797	14,3604	3.797	14,3604	54.526
2019-05-10	XOMA	BVF PARTNERS L P/IL	10.300	14,5667	10.300	14,5667	150.037
2018-12-17	XOMA	BVF PARTNERS L P/IL	25.000	14,1917	25.000	14,1917	354.792
2018-12-13	XOMA	BVF PARTNERS L P/IL	24.253	14,4116	24.253	14,4116	349.525
2018-12-12	XOMA	BVF PARTNERS L P/IL	2.810	14,7500	2.810	14,7500	41.448
2018-12-11	XOMA	BVF PARTNERS L P/IL	9.400	14,4968	9.400	14,4968	136.270
2018-12-10	XOMA	BVF PARTNERS L P/IL	18.081	14,5441	18.081	14,5441	262.972
2018-12-07	XOMA	BVF PARTNERS L P/IL	32.015	14,7674	32.015	14,7674	472.778
2018-12-06	XOMA	BVF PARTNERS L P/IL	10.927	14,7980	10.927	14,7980	161.698
2018-12-04	XOMA	BVF PARTNERS L P/IL	4.171	14,9880	4.171	14,9880	62.515
2018-12-03	XOMA	BVF PARTNERS L P/IL	806	14,9000	806	14,9000	12.009
2018-11-30	XOMA	BVF PARTNERS L P/IL	4.823	14,8486	4.823	14,8486	71.615
2018-11-29	XOMA	BVF PARTNERS L P/IL	10.016	14,9304	10.016	14,9304	149.543
2018-11-28	XOMA	BVF PARTNERS L P/IL	8.288	15,1136	8.288	15,1136	125.262
2018-11-27	XOMA	BVF PARTNERS L P/IL	11.396	15,2404	11.396	15,2404	173.680
2018-11-21	XOMA	BVF PARTNERS L P/IL	25.000	14,9957	25.000	14,9957	374.892
2018-11-20	XOMA	BVF PARTNERS L P/IL	37.482	13,6786	37.482	13,6786	512.701
2018-11-19	XOMA	BVF PARTNERS L P/IL	9.771	13,9253	9.771	13,9253	136.064
2018-11-16	XOMA	BVF PARTNERS L P/IL	10.849	13,8249	10.849	13,8249	149.986
2018-11-15	XOMA	BVF PARTNERS L P/IL	21.141	13,3088	21.141	13,3088	281.361

Handelsdato	Ticker	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2025-05-16	XOMA	BVF PARTNERS L P/IL	127.407	27,1000	127.407	27,1000	3.452.730	28	23.8500	-414.072	-11,99
2025-05-16	XOMA	BVF PARTNERS L P/IL	265.316	27,1000	265.316	27,1000	7.190.064
2025-01-24	XOMA	BVF PARTNERS L P/IL	339.679	26,1000	339.679	26,1000	8.865.622
2025-01-24	XOMA	BVF PARTNERS L P/IL	85.776	26,1000	85.776	26,1000	2.238.754
2025-01-24	XOMA	BVF PARTNERS L P/IL	75.287	26,1000	75.287	26,1000	1.964.991
2025-01-24	XOMA	BVF PARTNERS L P/IL	149.975	26,1000	149.975	26,1000	3.914.348
2021-03-31	XOMA	BVF PARTNERS L P/IL	279.740	38,3600	279.740	38,3600	10.730.826
2021-03-31	XOMA	BVF PARTNERS L P/IL	205.807	38,3600	205.807	38,3600	7.894.757
2021-03-31	XOMA	BVF PARTNERS L P/IL	84.250	38,3600	84.250	38,3600	3.231.830
2021-03-31	XOMA	BVF PARTNERS L P/IL	81.903	38,3600	81.903	38,3600	3.141.799